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Abstract 
 
Objectives 
This review examines the diagnostic accuracy and clinical utility of the Addenbrooke's 
Cognitive Examination (ACE) and its updated version, the Addenbrooke's Cognitive 
Examination – Revised (ACE-R), in relation to the diagnosis of dementia. 
Design 
A systematic search of relevant databases was conducted covering the period 2000 to 
April 2010 and specific journals and reference lists were hand searched.  Identified 
studies that fulfilled the inclusion criteria were reviewed using a tailored, methodological 
quality rating checklist. 
Results 
The systematic search process identified 9 studies for review (7 relating to the ACE, 2 on 
the ACE-R).  Each study is described individually before strengths and weaknesses across 
studies are considered.  Diagnostic accuracy measures are presented for 6 out of the 9 
studies. 
Conclusion 
The studies included in this review convey the ACE and ACE-R as tools capable of 
providing information on a range of cognitive domains and differentiating well between 
those with and those without cognitive impairment.  Further research examining how the 
tools distinguish between dementia subtypes and Mild Cognitive Impairment would 
further the evidence base. 
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Introduction 
 
Dementia is a disorder involving progressive, global, cognitive decline (Hannay et al., 
2004).  In 2005 it was estimated that 24.3 million people worldwide had dementia, with 
an anticipated worldwide increase of 4.6 million new cases per year (Ferri et al., 2005).  
Dementia diagnosis and the subsequent care pathway derived from the diagnosis is 
currently an area of high interest.  It has been estimated that only a third of those with 
dementia receive a diagnosis (National Audit Office, 2007), thus national priority 
benchmarks for NHS service providers have been implemented to increase rates of early 
diagnosis (for an example of this see the Scottish Government’s, Delivering for Mental 
Health, 2006).  Whilst under-diagnosis is described as 'the current norm' it has been 
recognised that early diagnosis can provide individuals with “...the chance to prevent 
future problems and crises and to benefit more from positive interventions” (Department 
of Health, 2009, p.7). 
 
There is an increasing evidence base to support this position.  For example, research has 
found that intervention following early diagnosis can improve quality of life and delay 
institutionalisation (Banarjee et al., 2009; Gaugler et al., 2005).  A prerequisite to 
effective post-diagnosis support must be an accurate assessment, capable of identifying 
individuals in the early stages of dementia.  Such an assessment would be maximally 
useful if it could identify the subtype of dementia and detail the cognitive domains 
showing impairment. This information is essential to enable appropriate early intervention 
and management (e.g. correct medication and symptom specific compensation strategies). 
 
Dementia is commonly used as an umbrella term for a set of progressive neurological 
conditions that cause cognitive impairment, including: Alzheimer's disease (AD), 
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Vascular dementia (VD), Fronto-temporal dementia (FTD), Lewy Body dementia (LB) 
and others.  Each subtype of dementia has its own symptom profile and disease course.  
However, commonalities exist between the different subtypes and between them and 
other disorders (e.g. depression and Vitamin B12 deficiency), this complicates the 
diagnostic process.  Before a dementia diagnosis can be established other possible causes 
of cognitive impairment should be ruled out; this includes confirming that the presenting 
symptoms are not due to normal age related changes. The term 'Mild Cognitive 
Impairment' (MCI) is used to describe individuals who present with a degree of memory 
impairment, but do not meet full diagnostic criteria for dementia.  A significant number of 
people with MCI will go on to develop dementia, though some will not: this group 
therefore requires accurate detection and monitoring. 
 
Screening tools in dementia assessment 
Potentially, cognitive screening tools offer a time-efficient, objective initial assessment of 
cognitive functioning.  The results from cognitive screening tools are not sufficient to 
make a diagnosis of dementia and should only be used as part of a comprehensive 
assessment (Smith et al., 2008).  Nonetheless, screening tools are typically judged by their 
ability to accurately distinguish between those with and those without dementia, based on 
cut off scores.  It has been noted that in several screening tool studies the dementia 
participants have severe cognitive impairment (Boustani et al., 2003).  These participants 
almost inevitably score poorly compared to healthy controls, who tend to perform near 
ceiling.  Studies which only compare these two participant groups fail to capture and 
represent the clinical utility required from a screening tool.  Evidence from such studies 
may aid detection of moderate or severe dementia, but be less accurate in detecting mild 
dementia (Boustani et al., 2003).  It has been stated that screening tools should be able to 
provide: 
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“...good sensitivity and specificity for all dementia types in unselected populations, and ... 
elicit information about key cognitive abilities, which can then be compared with 
neuropsychological profiles in different types of dementia” (Cullen et al., 2007, p.9). 
 
In 2000, the ACE was published as a screening tool to detect mild dementia and 
distinguish between Alzheimer's disease and Fronto-temporal dementia (Mathuranath et 
al., 2000).  The ACE incorporates the Mini Mental State Examination (MMSE), and 
includes items assessing the cognitive domains of: Attention and orientation, Fluency, 
Language, Visuospatial and Memory. Subscale scores are provided for each cognitive 
domain.  In 2006, a revised version of the ACE, the Addenbrooke's Cognitive 
Examination – Revised (ACE-R) was published (Mioshi et al., 2006).  Within the last 
decade the ACE has been cited as a potentially useful screening tool in guideline 
documents by the National Institute for Health and Clinical Excellence (NICE, 2006) and 
the Scottish Intercollegiate Guidelines Network (SIGN, 2006). 
 
Statistical assessment of screening tools 
Gifford and Cummings (1999) outlined guidelines on the methodological standards which 
should be reported for dementia screening tools.  They identified three measures of 
reliability (inter-rater reliability, intra-rater reliability and internal consistency) and three 
types of validity (content validity, construct validity and criterion validity - notably 
sensitivity and specificity), which “...should be evaluated and reported for a screening 
test” (Gifford and Cummings, 1999, p.224).  They also highlighted three potential sources 
of bias in screening tool studies.  These were: i) Spectrum bias (when the test varies 
across population subgroups e.g. age, gender); ii) Verification bias (when only patients 
scoring below the cut off point receive further gold standard assessment); iii) Review bias 
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(when the test under review and the gold standard are administered and/or interpreted by 
the same person). 
 
There is a recognised distinction between psychometric properties which are used to 
evaluate tests and those which contribute to interpretation of an individual's test results.  
Group comparison statistics (such as intra-rater reliability and construct validity) should 
not be used to support the clinician seeking to select the best tests to aid in diagnosing 
individual patients: criterion validity methods are a more helpful aid to such diagnostic 
decision making (Smith et al., 2008).  Table 1 defines the recommended measures for 
aiding clinical decision making (Smith et al., 2008).  These measures include: sensitivity, 
specificity, likelihood ratios (LR), positive predictive values (PPV), negative predictive 
values (NPV) and post test probabilities (PTP).  The PPV, NPV and PTP calculations 
require base rate information.  The base rate is the proportion of people in a larger 
reference sample (e.g. in the general population, or in people attending a memory clinic) 
who have the condition of interest.  Since the usefulness of dementia screening tools is 
primarily assessed using measures of diagnostic accuracy, a screening tool review will 
necessarily have to explore diagnostic accuracy, even though dementia screening tools 
should never be the sole means of diagnostic decision making. 
 
INSERT TABLE 1 HERE 
 
Systematic review objectives 
This review evaluates the literature available on the ACE and ACE-R with the following 
objectives: 
i)  To review the diagnostic accuracy of the ACE and ACE-R in diagnosing dementia. 
ii) To examine the evidence for utilising the ACE and ACE-R as cognitive profiling 
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tools for differential diagnosis. 
 
Method 
 
Search strategy 
The following electronic bibliographic databases were searched: All Evidence Based 
Medicine reviews, EMBASE, Medline, PsychINFO.  The search was limited to the time 
period 2000 to April 2010 because the original ACE paper was first published in 2000.  
The databases were searched using various search terms, including: “Addenbrooke*”, 
“dement*”, “screen*” and “cognitive impair*” (see Appendix 1.2 for full strategy).  Titles 
and abstracts of citations identified were examined to identify articles featuring either the 
ACE or the ACE-R.  The following journals were hand searched for the time period 2000 
to April 2010: Dementia and Geriatric Cognitive Disorders; International Journal of 
Geriatric Psychiatry.  Reference lists of the included studies were also checked to identify 
further relevant papers. 
 
Inclusion and exclusion criteria 
The titles and abstracts of papers identified as featuring the ACE or ACE-R were screened 
against the following inclusion and exclusion criteria. 
Inclusion Criteria: 
• Studies investigating the diagnostic accuracy of the ACE or ACE-R. 
• Studies considering the use of the ACE or ACE-R as tools for identifying and/or 
differentiating between types of dementia or between dementia and other 
disorders. 
• If more than one study used the same participants only the most up to date study 
was included. 
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Exclusion Criteria: 
• Studies that were not in English. 
• Studies that investigated translated versions of the ACE/ACE-R. 
• Studies that used the ACE/ACE-R to track changes in cognition over time. 
• Studies in which the tools featured only as part of a wider assessment; or the tools 
were not the primary focus of the study. 
• Response letters or guides were excluded and one study was also excluded 
because it was exclusively exploring the use of the ACE-R as a tool for identifying 
cognitive impairment in individuals who had a brain injury. 
Some of the excluded studies, where appropriate, will be commented on in the discussion. 
 
Assessment of methodological quality 
To rate the methodological quality of the included studies a rating checklist was devised 
based on the SIGN Methodology Checklist 5 for diagnostic studies (Scottish 
Intercollegiate Guidelines Network, SIGN, 2007) and the Standards for the Reporting of 
Diagnostic accuracy studies (STARD) statement (Bossuyt et al., 2003).  The rating 
checklist had a maximum score of 34 points (see Appendix 1.3 for a copy of the 
checklist).  All papers were rated by the author.  A second rater assessed 50% of the 
studies as a means of examining the inter-rater reliability of the checklist.  Across all the 
checklist items that were subject to inter-rater assessment, there was 84% agreement 
between the raters; where discrepancies occurred, these were resolved through discussion. 
 
Results 
 
Outcome of search process 
Forty-five ACE or ACE-R studies were initially identified; of which nine papers met the 
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inclusion criteria.  Figure 1 provides a flow diagram outlining the systematic process of 
identifying the nine studies discussed in this review from the initial forty-five ACE or 
ACE-R studies.  A reference list of the excluded studies is provided in Appendix 1.4. 
 
INSERT FIGURE 1 HERE 
 
Whilst the studies included have in common a focus on either the ACE or ACE-R as a 
tool to distinguish between those with and those without cognitive impairment or between 
different types of cognitive impairment, there is nonetheless, substantial heterogeneity 
between them.  Each study will be reported individually before commonalities and 
differences between the studies are highlighted.  ACE and ACE-R studies are reported 
separately.  A summary table of demographic information across studies is provided in 
Table 2. 
 
INSERT TABLE 2 HERE 
 
Table 3 provides a summary of the key strengths and limitations identified by the rating 
checklist for each study.  Studies are described below in order of their score on the 
methodological checklist. 
 
INSERT TABLE 3 HERE 
 
Review of findings for ACE papers 
Mathuranath et al. (2000): 27/34 on the rating checklist. 
This was the original article introducing the ACE.  It aimed to validate the ACE as a 
screening tool to detect mild dementia and differentiate between Alzheimer's disease 
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(AD) and Fronto-temporal dementia (FTD).  The study consisted of a clinic group 
referred to a memory clinic (diagnosed independently of the ACE) and controls.  The 
control and clinic groups excluded individuals if they had major depression, mixed 
dementia or cognitive impairment of non neurodegenerative aetiology (e.g. alcoholism).  
 
Two cut off points were identified for distinguishing between participants with dementia 
and those without.  The 88/100 cut off point was developed via calculation of two 
standard deviations below the mean composite score for the control group.  The other cut 
off (83/100) was determined by estimating the probability of diagnosing dementia in the 
clinic group, at varying potential cut offs and selecting the optimal one.   
 
Different performance profiles were identified across the subscale scores for AD and FTD 
groups.  The FTD patients performed better on tests of orientation and delayed memory, 
whilst the AD group did relatively better on language and fluency items; these results are 
consistent with established neuropsychological profiles of the two dementia subtypes.  
The 'VLOM ratio' was introduced as a proposed method for distinguishing between AD 
and FTD, by comparing scores on verbal fluency and language items to those on 
orientation and delayed memory recall.  Maximal sensitivity and specificity details for the 
VLOM ratio were provided.  Mathuranath et al. (2000) investigated the internal 
consistency, criterion validity and construct validity of the ACE.  It was concluded that 
the ACE maintained good sensitivity across different subtypes and severity of dementia as 
defined by Clinical Dementia Ratings (CDR).  The CDR provides an indicator of an 
individual’s stage in the disease process. 
 
Dudas et al. (2005): 25/34 on the rating checklist. 
The aim of this study was to investigate the ability of the ACE to distinguish between 
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cognitive deficits resulting from dementia, versus those from affective disorders.  In 
addition to dementia groups the study included a group of participants with Major 
Depressive Disorder (MDD); a group with affective symptoms and a mixed group (in 
which it was unclear if their impairment was due to a dementia or an affective aetiology).  
A significant difference in ACE performance was found between controls compared to the 
dementia and mixed groups.  There was no significant difference between the MDD, 
affective and control groups.  When cognitive domains were examined, a combined 
affective and MDD group was significantly impaired in memory and verbal fluency 
compared to controls.  The mixed group was indistinguishable from AD and FTD groups 
on the category and verbal fluency items.  In the mixed group, 15 out of 16 patients 
scoring lower than 88/100 on the ACE at initial assessment had a confirmed dementia 
within 2 years. 
 
Davies et al. (2008): 24/ 34 on the rating checklist. 
This study aimed to assess the ACE's ability to differentiate between Alzheimer's disease 
(AD) and Semantic dementia (SD, a subtype of Fronto-temporal dementia).   ACE items 
were grouped into 12 sub scores and performances on these sub scores were compared 
between the SD and AD groups.  SD participants performed significantly poorer on 
naming and reading items, whereas AD participants were significantly poorer on 
orientation items.  A 'semantic index' was developed which consisted of the naming and 
reading scores, serial 7s, orientation in time and drawing scores.  Values of less than zero 
on the index were found to be predictive of SD rather than AD, with 88% sensitivity and 
90% specificity.  The study did not detail how the AD participants were recruited and how 
and when their diagnosis of AD was made.  It is also unclear when the AD participants 
completed the ACE.  The discussion does not provide guidance about when in clinical 
practice this proposed semantic index should be utilised and whether it should be used in 
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addition to, or instead of the VLOM, which was introduced by Mathuranath et al. (2000). 
 
Galton et al. (2005): 21/34 on the rating checklist. 
The aim of this study was to address the relative value of the ACE in comparison with 
more detailed, neuropsychological tests and evaluation of the medial temporal lobe (via 
magnetic resonance imaging, MRI) in predicting participant conversion from 
questionable dementia (QD, a concept similar to MCI) to Alzheimer's disease (AD).  The 
ACE had the best combination of Positive Predictive Value (PPV) and sensitivity 
compared to other neuropsychological tests, for predicting participant conversion from 
QD to AD.  An ACE cut off of 80 provided best separation between converters and non 
converters and was the single best predictor of progression to AD; more so than 
neuropsychological tests evaluating one cognitive domain and MRI imaging results.  The 
study reports sensitivity and specificity values for the ACE; however, it does not 
explicitly report which ACE cut off point these values are for, presumably they are for a 
cut off score of 80. 
 
Reyes et al. (2009): 19/34 on the rating checklist. 
This study investigated the validity of the ACE as a means of assessing cognitive function 
in patients with Parkinson's disease (PD).  Participants from a PD outpatient clinic were 
recruited (n=44).  Participants were excluded if they had depression, dopamine 
dysregulation syndrome, a history of drug abuse, cognitive decline secondary to a 
systemic or other degenerative disease.  The Mattis Dementia Rating Scale (MDRS) was 
used as the gold standard reference method.  The study used a variety of tools to measure 
the disease progression and the symptoms of Parkinson's.  The ACE and the MDRS were 
found to correlate well (r = 0.91, p<0.0001), thus it was concluded that the ACE was a 
valid tool for dementia evaluation in PD. 
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Larner (2007a): 19/34 on the rating checklist. 
Larner's (2007a) study reports ACE data from 285 consecutive patients referred with 
cognitive complaints to a cognitive function clinic, there was no participant exclusion 
criteria.  All participants received a full assessment (including 1 year follow-up) and were 
subsequently classified, independently of their ACE performance, as individuals with 
either dementia or non-dementia.  The study did not provide any demographic 
information on the participants recruited nor on what conditions were present in the group 
defined as ‘non dementia’.  The 88 and 83 cut offs reportedly had good sensitivity but 
poorer specificity; an alternative cut off of 75 improved specificity.  The VLOM ratio was 
found to have reasonable sensitivity and specificity for the recommended cut off proposed 
by Mathuranath et al. (2000) to indicate AD; however, sensitivity for the FTD cut off was 
poor.   
 
Bak et al. (2005): 14/34 on the rating checklist. 
The aim of this study was to examine the cognitive profile of three subcortical dementia 
disorders associated with parkinsonism (Progressive supranuclear palsy (PSP), 
Corticobasal degeneration (CBD) and Multiple systems atrophy (MSA)) compared with a 
group of participants with AD and a group of healthy controls.  The ACE and the 
Dementia Rating Scale (DRS) were used to compare the different participant groups.  The 
AD participants were recruited through a memory clinic and the parkinsonism 
participants were recruited from other studies (PSP, Litvan et al., 1996; MSA, Gilman et 
al., 1998; CBD, Riley and Lang, 2000).  Two of the subcortical dementia groups (PSP and 
CBD) along with the AD group were significantly impaired on the ACE total score, 
compared to controls; however, the ACE did not detect cognitive impairment in the other 
subcortical group (MSA); the verbal fluency sub test was the only subscale score which 
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distinguished between this group and the controls. 
 
Review of findings for ACE-R papers 
Mioshi et al. (2006): 23/34 on the rating checklist. 
This article introduced the ACE-R and aimed to validate the clinical utility of the 
revisions of the ACE.  Three groups of participants were included in the study: dementia 
(AD, FTD, LB), healthy controls and MCI.  Participants were excluded if they had a 
psychiatric disorder, mixed dementia or cognitive impairment caused by something other 
than a neurodegenerative disease.  Two cut off scores were defined (88 and 82) based on 
sensitivity, specificity and positive predictive value calculations at different prevalence 
rates.  Participant performance on the ACE compared to the ACE-R was investigated; 
however, it is unclear when the ACE and ACE-R were undertaken in relation to each 
other.  A subgroup of age and education matched participants was elicited from control, 
AD, and MCI groups; from these subgroups the MCI group performance was found to be 
between the AD and control groups, although a suggested cut off point for the MCI group 
was not given and the small numbers in each group limits the conclusions that can be 
drawn. 
 
The study reported that spectrum bias was avoided by: “including participants with 
different dementia syndromes and with a broad range of impairment (MMSE scores 
ranging from 9 to 30)” (2006, p.1084).  It is unclear if reported MMSE scores are 
extracted from ACE-R results or if they were completed separately.  Concurrent and 
convergent validity and reliability were explicitly assessed and reported to be ‘significant’ 
and ‘good’.  Mioshi et al. (2006) provide a table reporting the positive likelihood ratios of 
dementia at a range of cut off points. 
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Larner (2007b): 13/34 on the rating checklist. 
This article is a brief research letter which describes a prospective study of the ACE-R 
conducted for 100 consecutive patients referred to a cognitive function clinic.  The 
breakdown of the subsequent diagnoses that these participants received is included.  The 
sensitivity and specificity of the ACE-R for identifying dementia at the cut off scores of 
88 and 82 are provided.  Results for a cut off score of 75 are also provided.  The study 
concludes that the ACE-R has good sensitivity and that in clinical practice test specificity 
and positive predictive value may be improved by a lower cut off. 
 
Critical review of studies 
The studies which rated highest on the rating checklist were: Mathuranath et al. (2000), 
Dudas et al. (2005), Davies et al. (2008) and Mioshi et al. (2006) (scoring 27, 25, 24, and 
23 respectively).  The studies which had the lowest scores on the rating checklist were: 
Bak et al. (2005) and Larner (2007b) (14 and 13 respectively). 
 
Most studies used the reference standard, the National Institute of Neurological and 
Communicative Disorders and Stroke/Alzheimer’s disease and Related Disorders 
Association criteria (NINCDS-ADRDA, McKhann et al., 1984), with the exception of 
Reyes et al. (2009) who used the Mattis Dementia Rating Scale.  Most studies (except the 
two Larner studies 2007, a+b) provide demographic information in terms of participant 
sex and average age.  Four studies also provide information on years of education 
(Mathuranath et al., 2000; Dudas et al., 2005; Mioshi et al., 2006; Reyes et al., 2009) and 
four on severity of symptoms using the CDR (Mathuranath et al., 2000; Mioshi et al., 
2006; Galton et al., 2005; Dudas et al., 2005).   
 
In 2007 a study reported that years of education had a significant impact on performance 
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on the Malaysian version of the ACE (Mathuranath et al., 2007).  Whilst this does not 
necessarily mean the same is true for the English version, it does highlight the need for 
educational experience to be routinely reported and for future research to explore whether 
or not education is a potential moderating factor for ACE/ACE-R performance.  Since the 
impact of education on ACE/ACE-R performance requires further investigation it is 
unclear whether or not it is a potential source of spectrum bias.  Furthermore, since a 
criticism of screening tool studies has been that their dementia participants often have a 
more severe level of dementia (Boustani et al., 2003) it would be beneficial if dementia 
symptom severity was routinely reported. 
 
Under reported elements across most of the studies, (with the exception of Mathuranath et 
al., 2000 and Dudas et al., 2005) were the numbers, training and expertise of the persons 
administering and interpreting the ACE/ACE-R and the reference standard.  With the 
exception of Larner (2007a) all of the studies failed to explicitly state if the ACE/ACE-R 
results were interpreted without knowledge of the reference standard results.  With these 
two factors not being consistently reported it is not possible to know if there was a review 
bias present in most of the studies.  Included studies also lacked information on how they 
assessed the reference standard (e.g. what specific tests, interview schedules and scans 
were used).  Without this information it is difficult to judge how detailed these assessment 
were. 
 
Four of the studies (Larner 2007 a+b; Reyes et al., 2009; Bak et al., 2005) did not report 
the period of time between administration of the reference standard and ACE/ACE-R.  
Whether or not the reference standard was independent of the ACE/ACE-R (i.e. the 
ACE/ACE-R did not form part of the reference standard) was not explicitly mentioned in 
three of the articles.  In addition Mioshi et al. (2006) and Galton et al. (2005) report using 
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the MMSE as part of the assessment for the reference standard.  Since the MMSE is 
incorporated within the ACE/ACE-R this indicates that there was not complete 
independence between the reference standard and the ACE/ACE-R, this is an area that 
both STARD and SIGN diagnostic checklists highlight, because overlap here may 
introduce bias (Bossuyt et al., 2003; SIGN, 2007).  Furthermore, the majority of studies, 
with the exception of Reyes et al. (2009) and Galton et al. (2005), do not mention if there 
were any drop outs/deaths in the studies. 
 
In several studies the ACE/ACE-R was administered at initial assessment to a group of 
participants with unknown aetiologies and reviewed once subsequent diagnostic decisions 
had been made (Mathuranath et al., 2000; Larner, 2007a+b; Reyes et al., 2009).  This 
methodology minimises verification bias because it means all those in the clinical group 
receive both the ACE/ACE-R and reference standard.  However in studies involving a 
control group, although not explicitly reported, it appears to the reader that none of the 
participants in the control groups received the reference standard; which means 
verification bias cannot be ruled out.  In addition it is unclear from the studies how many 
participants required follow up assessment to establish diagnosis.  If follow up was 
required it seems possible (depending on the time elapsed) that presentation could have 
altered from when the ACE/ACE-R was originally completed. 
 
Mathuranath et al. (2000) and Mioshi et al. (2006) reported internal consistency and 
convergent validity.  None of the studies included in this review assessed inter-rater or 
intra-rater reliability.  In terms of the criterion validity, most studies reported sensitivity 
and specificity information.  However, sensitivity and specificity values cannot assist 
clinicians in making decisions about the probability of disease in individual patients 
(Akobeng, 2006; Grimes and Schulz, 2002).  Only Larner (2007a+b) and Mioshi et al. 
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(2006) report likelihood ratios.  Furthermore, only Mathuranath et al. (2000), Mioshi et al. 
(2006), Galton et al. (2005) and Larner (2007a+b) report predictive values; however, the 
Larner studies (2007a+b) do not report the base rates used to calculate these values. 
 
This review calculated the positive and negative likelihood ratios for all included studies 
which had provided relevant sensitivity and specificity information for ACE/ACE-R cut 
offs. Furthermore, using estimated base rate information, predictive values and post test 
probability values were also calculated. These values are available in Table 4. 
 
INSERT TABLE 4 HERE 
 
The base rates used are based on information regarding the prevalence of dementia at 
memory clinics in England and the prevalence of dementia in the general population of 
people aged between 60-69, because the average age of participants in the majority of 
studies is within this age range.  The memory clinic base rate for dementia was taken as 
54% (NICE, 2010), whilst the base rate for dementia in the general population aged 60-69 
was estimated to be 1.3% (Knapp and Prince, 2007). 
 
Discussion 
 
The ACE and ACE-R are screening tools designed to aid in the detection of dementia.  In 
the research covered in this review, they have been applied to a range of populations; 
different cut off scores have been identified and some consideration has been given to 
symptom profiles.  Table 4 demonstrates that across the range of studies the ACE/ACE-R 
remain statistically robust, although the PPV, NPV and PTP results for the population and 
memory clinic base rates emphasise that underlying base rate has a significant influence 
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on the probability of a patient in clinical practice with a given result actually having 
dementia.  It is essential that if these values are reported in the literature readers know the 
base rates they are derived from, so that they may compare them to the base rates in their 
own clinical context. 
 
Across the majority of reviewed studies there was a lack of information on: number, 
training and expertise of the persons executing and interpreting the ACE/ACE-R and 
reference standard; withdrawals; if the ACE/ACE-R results were interpreted without 
knowledge of the reference standard results and how the reference standard assessment 
was conducted.  These are items that SIGN and/or STARD diagnostic accuracy guidelines 
consider important and their absence means that it is not possible to know the potential 
for verification and review bias present in these studies.  Future ACE/ACE-R studies 
would benefit from including this information. 
 
In the studies included in this review there was also a lack of information on how those 
with Vascular dementia and Lewy Body dementia perform on the ACE/ACE-R.  Vascular 
dementia is the second most common type of dementia (after AD), thus how patients with 
Vascular dementia perform on the ACE/ACE-R deserves further investigation. 
 
Diagnostic accuracy 
To be fit for use clinically, screening tools need to have statistically robust cut off scores. 
This allows distinction between individuals who are in the early stages of a dementia and 
those who may have a mild cognitive impairment of a different aetiology or no 
impairment at all.   
 
The original articles by Mathuranath et al. (2000) and Mioshi et al. (2006) scored highly 
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on the rating tool and provide two cut off points for differentiating between those with 
and those without dementia. The Larner studies (2007a+b) did not score as highly on the 
rating tool, due mainly to missing information, nonetheless they offer an alternative cut 
off based on an unselected participant group.  Therefore, there are currently three 
potential cut offs identified in the literature for the ACE (88, 83, 75) and the ACE-R (88, 
82, 75). 
 
Galton et al. (2005) reported that a cut off score of 80 on the ACE was best at 
distinguishing between those with questionable dementia who converted to dementia and 
those who did not, two years post assessment.  Dudas et al. (2005) reported that in their 
‘mixed’ group (affective and dementia symptoms) of the participants who scored below 
88 on the ACE, 15/16 went on to develop dementia.  A study not included in this review, 
followed up groups of participants diagnosed with MCI at 2 years post diagnosis 
(Mitchell et al., 2009).  The study found that a combination of the ACE and the Paired 
Associates Learning (PAL) test was predictive of status after 2 years, concluding that 
those scoring >88 on the ACE and <14 errors on the PAL were at low risk of dementia.  
Therefore it would seem that in clinical practice those scoring below 88 are at an 
increased risk of dementia, and thus require further assessment and monitoring. 
 
Taking into account the reviewed literature and the information from Table 4 it would 
seem that the 88 cut off is able to distinguish well between those with some degree of 
cognitive impairment and those without.  Conversely a cut off score of 75 seems to 
capture those who are highly likely to have dementia.  The 83 cut off and indeed any 
score between 75-88 may be suggestive of an early dementia or mild cognitive 
impairment.  Due to the different participant groups across studies it is not possible to 
provide more specific information on these cut off scores.  In Mathuranath et al. (2000) 
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the 83 cut off had good sensitivity, specificity, likelihood ratios and post test probabilities 
(in memory clinic base rate), for distinguishing between dementia and non-dementia in a 
clinic group.  However, it is not clear if the clinic group participants classified as ‘non 
dementia’ had some level of mild cognitive impairment.  Furthermore, exclusion criteria 
had been applied to the clinic group, omitting those with psychiatric disorders, mixed 
dementias and cognitive impairments of non neurodegenerative aetiology.  Clinicians 
using the ACE/ACE-R in clinical practice should refer to the information in Table 4 as a 
guide to aid assessment when considering individual scores.  It is essential that when 
Table 4 results are interpreted the participant groups involved in each study are taken into 
account. 
 
Grimes and Schulz (2002) note that information gained from the measurements available 
in Table 4 are: 
 
“Predicated on an assumption that is often clinically unrealistic i.e. that all people can be 
dichotomized as ill or well.  Often those tested simply do not fit neatly into these 
designations: they might be possibly ill, early ill, probably well or some other variety” 
(p.882). 
 
This statement is consistent with the results for the current review, because it is not clear 
whether or not the ACE/ACE-R is able to distinguish between MCI and dementia, and if 
it is what the cut offs for MCI should be.  This highlights why screening tools, in 
isolation, are not sufficient means of diagnosis. 
 
Utility of the ACE/ACE-R for differential diagnosis 
The original article presenting the ACE suggested that AD and FTD groups could be 
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distinguished by their subscale scores.  It was hypothesised that those with AD would be 
more impaired on the orientation and delayed memory recall items while those with FTD 
would be more impaired on verbal fluency and language items.  The VLOM ratio was 
introduced as a means of objectively measuring this contrasting pattern in performance.  
The VLOM ratio has been investigated in three of the nine studies in this review.  
Mathuranath et al. (2000) and Mioshi et al. (2006) conclude that it is a useful ratio to 
calculate, whereas Larner (2007a) questions its specificity.  Interestingly a paper not 
included in this current review explored the VLOM in the French version of the ACE and 
found that only 1 out of 9 patients with Fronto-temporal dementia were identified using 
the recommended VLOM cut offs (Bier et al., 2004).  However, the FTD patients in this 
study all presented with ‘the pure frontal form’ of the disease.  In another study by Mioshi 
et al. (2007) the relationship between the ability to perform activities of daily living and 
cognitive dysfunction was investigated across three variants of Fronto-temporal dementia.  
The ACE-R was used in the study as a measure of cognition.  The study concluded that 
Fronto-temporal dementia has a significant impact on activities of daily living but that 
this impairment is not captured by the ACE-R.  Mioshi et al. (2007) suggested that the 
ACE-R may have limited ability to detect FTD.  It therefore remains uncertain whether 
the VLOM is a clinically useful measure. 
 
Davies et al. (2008) reported an index for distinguishing Semantic dementia from 
Alzheimer's disease.  However, no other study has examined this index and so it is not 
possible to conclude from the current review what its clinical utility is.  The subtests 
implicated in this index as being more impaired in SD participants were naming and 
reading, whereas orientation items were reported as more impaired for AD participants.  
In Dudas et al.'s (2005) study there was no significant difference between the major 
depressive disorder, affective and control groups.  However, when the cognitive domains 
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were examined a combined affective and MDD group was significantly impaired in 
memory and verbal fluency compared to the controls. 
 
Based on the articles in this review, it would seem that there is not, as yet, a well 
established evidence base for certain subscale profile patterns on the ACE/ACE-R being 
indicative of certain disorders.  However, this does not detract from the fact that the 
subscale information available in the ACE/ACE-R is a key strength of these tools.  This 
information enables clinicians with knowledge of the neuropsychological profiles of 
different dementia subtypes, to obtain qualitatively rich information from patient subscale 
performance.  Such information can assist in guiding further assessment.  Therefore the 
subscales offer an important source of information to clinicians who have the expertise to 
extract qualitative information from them. 
 
Limitations of the review 
This review did not include studies investigating translated versions of the ACE/ACE-R.  
During the initial search stage of this review sixteen such studies were identified, 
indicating that these studies form a significant part of the ACE/ACE-R literature base 
which this review is unable to comment on.  Thus, a future review of the translated 
studies would be desirable. 
 
A further limitation of this review concerns the adapted methodological checklist used to 
assess quality in the articles included.  Since screening tools should never be used in 
isolation to make diagnostic judgements it may be that the rating checklist had limited 
applicability because it was based on diagnostic accuracy guidelines.  The guidelines for 
diagnostic tests are perhaps more suited to medical tests rather than assessments of 
cognitive function.  This review adapted diagnostic guidelines and took into account 
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guidelines for dementia screening tools (Gifford and Cummings, 1999), in an attempt to 
minimise any rating checklist difficulties. 
 
Areas for future research 
None of the included studies in this review assessed the intra-rater or inter-rater reliability 
of the ACE/ACE-R.  Without this information it is not possible to know if the ACE/ACE-
R are reliably scored across different raters and by the same raters at different time points.  
These issues should be addressed in future research.  This review also identified that 
whilst sensitivity and specificity were widely reported other measures of diagnostic 
accuracy, which are a greater aid to clinical decision making, LRs, PPV, NPV and PTP 
were not routinely reported.  It would be beneficial for future understanding and 
comparison among ACE/ACE-R studies if this information could be routinely reported; 
this would include explicitly reporting the base rates used in calculations. 
 
Additionally, in this review none of the articles provided any indicator about whether or 
not conclusions drawn in studies about the ACE are applicable to the ACE-R.  It would be 
helpful if this could be clarified in future as the majority of studies in this review use the 
ACE (7vs.2), however it has now been widely replaced by the ACE-R in clinical practice. 
 
Conclusions 
 
This review suggests that statistically the ACE and ACE-R are robust tools for detecting 
cognitive impairment and has provided readers with information on diagnostic accuracy, 
which they may refer to when reviewing individual patient performance on the 
ACE/ACE-R.  The ability of the tool to distinguish between MCI and dementia and also 
between dementia subtypes is an issue which requires further research.  Currently there is 
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not enough evidence to advocate the use of certain subscale symptom profiles; 
nonetheless domain subscale information offers a rich source of qualitative information to 
aid the assessment process. 
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Table 1: Definitions 
 
Measure Definition* Interpretation* 
 
Sensitivity 
(Sn) 
 
The proportion of people with the target disorder 
who have a positive test result.   
 
The following mneumonic is used to understand sensitivity:  
High Sensitivity means a Negative result rules out the diagnosis (SNOUT). 
 
Specificity 
(Sp) 
The proportion of people without the target disorder 
who have a negative test result.   
The following mneumonic is used to understand specificity:  
High Specificity means a positive result rules in the diagnosis (SpPIN). 
 
Likelihood 
Ratio for a 
positive test 
(LR +) 
The probability an individual with the disease will 
have a positive test, divided by the probability of an 
individual without disease having a positive test 
result. 
An LR+ greater than 1 means a positive test result is more likely to occur in those 
with the disease than in those without.  For disease prevalence of 10-90% a LR+ of 
2 increases the probability of disease by 15%, LR+ of 5 by 30%, LR+ of 10 by 
45%. 
 
Likelihood 
Ratios for a 
negative test 
(LR-) 
 
The probability of an individual with disease 
having a negative test, divided by the probability of 
an individual without disease having a negative 
result. 
 
An LR- of less than 1 means a negative result is less likely to occur in people with 
the disease compared to those without.  For disease prevalence of 10-90% a LR- of 
0.5 reduces the probability by about 15%, LR- of 0.2 by 30% and LR- of 0.1 by 
45%. 
 
Positive 
Predictive 
Value (PPV) 
 
 
The proportion of people with positive test results 
who actually have the disease 
 
To judge the probability an individual patient has/does not have the target disorder 
based on the PPV and NPV values of their score one must ensure the patient meets 
the inclusion/exclusion criteria applied in the study and that the prevalence rate in 
the study is approximately the same as that in the area the patient is from.  If the 
prevalence rate of the disease is low then the PPV will not be close to 1, even when 
the sensitivity and specificity are high.   
Negative 
Predictive 
Value (NPV) 
 
The proportion of people with  negative test results 
who do not have the disease 
Post test 
probability 
 
The proportion of patients with that particular test 
result who have the condition of interest.   
This result will vary depending on the underlying base rate.  It allows an individual 
patient’s probability of having the disease after the test result is known to be 
reported.  It allows statements like “Based on the patient having earned a score of y 
on test z the probability that this patient has the condition of interest is x” (where x 
is the post test probability). 
 
* Information in table taken from Akobeng (2006), McGhee (2002) and Smith et al. (2008). 
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Studies involving the 
ACE/ACE-R 
n = 45. 
16 were excluded because their 
focus was on translated 
versions of the ACE or ACE-R.  
3 studies were excluded because 
they were letters responding to 
other articles. 
1 was excluded because it was a 
review/guide article. 12 studies were excluded 
because the ACE/ACE-R was 
used in them to track changes 
over time; or as part of a wider 
assessment; or was not the 
main measure of interest within 
the study. 
Studies included in the review, n = 9. 
Figure 1: Flow diagram 
Databases Searched: 
MEDLINE 
EMBASE 
All EBM Reviews 
PsychINFO 
Total studies identified: n=1243. 
3 studies were excluded 
because their participant groups 
were the same as those used in 
other studies. 
1 study was excluded because 
its participant group was made 
up of individuals who had 
experienced brain injury. 
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Table 2: Demographic Information* 
Study ACE/ 
ACE-R 
Gold standard Participant type Participant 
number 
No. of 
Males 
Age in years  
(SD) 
Education in 
years (SD) 
Mean total score 
(SD) 
Mathuranath et al. 
2000 
ACE DSM-IV, NINCDS/ADRDA, NINDS-
AIREN and the FTD consensus 
criteria 
Dementia 115 61 66.6 (8.9) 11.1 (2.6) 64.8(18.9) 
Non dementia 24 19 63.8 (7.0) 12.7 (3.6) 88.0 (8.2) 
Controls 127 63 64.4 (9.3) 11.3 (2.6) 93.8 (3.5) 
Dudas et al. 2005 ACE NINCDS/ADRDA, FTD Consensus 
criteria 
AD 63 27 68.9(8.0) 10.6(2.3) 61.9(18.3) 
FTD 27 18 61.3(7.3) 11.3(2.7) 74.2(15.4) 
MD 23 11 59.1(7.9) 11.2(1.7) 89.2(9.2) 
Affective 37 21 54.4(10.2) 12.4(3.1) 89.0(9.2) 
Mixed 22 12 64.1(8.1) 11.1(2.9) 71.0(16.6) 
Control 127 63 64.4 (9.4) 11.3(2.6) 93.9(3.5) 
Davies et al. 2008 ACE NINCDS-ADRDA, FTD Consensus 
criteria 
SD 40 25 62.9(7.0) NS 56.7(20.3) 
AD matched MMSE 40 25 66.7 (8.8) NS 68.3 (19.9) 
AD matched ace 40 25 67.2 (7.9) NS 56.7 (20.3) 
Galton et al. 2005 ACE NINCDS/ADRDA,  Early AD 19 7 66.9 (8.4) NS 64.0 (7.4) 
QD convert 11 6 70.9(8.9) NS 78.6 (7.5) 
QD non convert 18 8 9.3(7.8) NS 91.4 (3.6) 
Reyes et al. 2009 ACE MDRS PD dementia 13 9 68.6 (11.5) 11.9 (5) 71.7 (8.9) 
PD non dementia 31 18 71.9 (10.5) 14.3 (3.4) 89.8 (6.1) 
Larner 2007a ACE NINCDS/ADRDA, DSM-IV, 
Consortium on DLB, FTD consensus 
criteria, NINDS-AIREN 
Non dementia 145 NS NS NS NS 
Dementia 140 NS NS NS NS 
Bak et al. 2005 ACE NINCDS AD 30 NS 69.3 (8.3) NS 71.7 (14.0) 
PSP 39 NS 69.2 (5.8) NS 78.8 (10.2) 
CBD 25 NS 67.1 (7.5) NS 63.9 (21.7) 
MSA 26 NS 65 (7.2) NS 85.5 (8.5) 
Controls 30 NS 71.3 (5.5) NS 94.4 (3.0) 
Mioshi et al. 2006 ACE-R NINCDS/ADRDA, 
FTD consensus, Consortium on LB 
Dementia 142 99 68.8(9.0) 12.8(3.4) 65.4(15.9) 
MCI 36 17 64.4(5.7) 12.7(2.1) 84.2(7.3) 
Control 63 28 60.9(11.6) NS 93.7(4.3) 
Larner 2007b ACE-R NS Dementia AD 33 NS NS NS NS 
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Dementia FTD 8 NS NS NS NS 
Dementia VD 2 NS NS NS NS 
Dementia LB 1 NS NS NS NS 
Non dementia MCI 18 NS NS NS NS 
Non dementia 
Affective 
10 NS NS NS NS 
Non dementia PSMI 25 NS NS NS NS 
 
*Table 2 Abbreviations Key 
AD        Alzheimer's disease Affective    Affective disorder CBD Corticobasal degeneration 
Convert  Converter from QD to dementia FTD        Fronto-temporal dementia LB Lewy body dementia 
MCI Mild cognitive impairment MD         Major Depressive disorder Mixed Mixed presentation of dementia & depression 
symptoms 
MSA Multiple systems atrophy NS Not specified Non convert  Non converter from original QD diagnosis 
PD Parkinson's disease PSMI Primarily subjective memory impairment PSP Progressive supranuclear palsy 
QD        Questionable dementia VD Vascular dementia   
Consortium 
on LB 
 
Consensus guidelines for the clinical and 
pathologic diagnosis of dementia with Lewy 
bodies 
DSM-IV Diagnostic and statistical manual of mental disorders 
– Fourth edition 
FTD consensus 
criteria 
Fronto-temporal lobar degeneration: a consensus 
on clinical diagnostic criteria 
MDRS Mattis Dementia Rating Scale NINCDS/ 
ADRDA 
 National Institute of Neurological and 
Communicative disorders and stroke and the 
Alzheimer’s disease and Related Disorders 
Association 
NINDS 
-AIREN 
National Institute of Neurological Disorders and 
Stroke-Association Internationale pour la 
Recherche et l’Enseignement on Neurosciences 
criteria 
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Table 3: Summary of rating checklist results 
 
Study Rating Strengths  Limitations 
Mathuranath 
et al., 2000 
27/34 - Clear selection criteria and participant recruitment 
information.  
 
- Adequate information about the ACE and the reference 
standard in terms of their execution and the period of time 
between them.     
 
- Reference standard independent of the index test and likely 
to classify the condition correctly. 
 
- Demographic information provided and diagnostic accuracy 
statistics reported. 
 
- No report of whether or not the results were interpreted without 
knowledge of the results of the reference standard.  
 
- Unknown if there were any withdrawals from the study. 
 
- More information on researchers qualifications and roles 
within the study; details about the timescale of the study and a 
less specific participant group would have been helpful. 
Dudas et al., 
2005 
25/34 - Clear selection criteria and participant recruitment 
information. 
 
- Range of participant groups included. 
 
- Reference standard likely to classify the condition and 
independent of the ACE. 
 
- Time period between ACE and reference standard reported.   
 
- Study timescale information and demographic information 
reported. 
 
- No report of whether the ACE was interpreted with or without 
knowledge of the reference standard. 
 
- No information on any study withdrawals. 
 
- More information on the researchers involved; the execution of 
the ACE and the execution of the reference standard would have 
been helpful. 
 
Davies et al., 
2008  
24/34 - Clearly explained participant recruitment. 
 
-  Reference standard likely to classify the condition and 
independent of the ACE. 
 
- No information on the researchers involved. 
 
-  No report of whether the ACE was interpreted with or without 
knowledge of the reference standard. 
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- Execution of the ACE explained. 
  
- Time period between reference standard and the ACE 
seemed reasonable. 
 
- Demographic information provided and timescale of the 
study reported. 
   
- No mention of whether or not there were any study 
withdrawals. 
 
- Quite selective participant group. 
 
- More information on the selection criteria; execution of the 
reference standard and the statistical analyses would have been 
helpful.  
 
Galton et al., 
2005 
21/34 - Clear selection criteria and participant recruitment 
information. 
 
- Considers ACE application in an MCI group. 
 
- Reference standard likely to classify the condition. 
  
- Details on the execution of the ACE provided. 
 
- Information on withdrawals from the study provided. 
 
- Details of the study timescale reported.   
- No information on when the ACE was administered during the 
study and by whom.  
 
- The MMSE was used as part of the assessment of the reference 
standard.   
 
- Lack of information on the execution of the reference standard. 
 
- No report of whether the ACE was interpreted with or without 
knowledge of the reference standard. 
 
- More demographic information and statistical reporting would 
have been helpful. 
 
Reyes et al. 
2009 
19/34 - Clear selection criteria and participant recruitment 
information. 
 
- Reference standard was independent of the ACE. 
 
- Demographic information provided. 
 
- Statistical analyses seemed appropriate. 
- Lack of information on the researchers involved in the study. 
 
- Period of time between the reference standard and ACE not 
reported.  
 
-  No report of whether the ACE was interpreted with or without 
knowledge of the reference standard. 
 
- No information on study withdrawals. 
 
- Study timescale not reported 
 
- More information on the execution of the index and reference 
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standards and whether the reference standard selected was likely 
to classify the condition would have been helpful. 
 
Larner, 
2007a 
19/34 - Good representative sample of participants and selection 
criteria are mentioned. 
  
- Reference standard independent of the index test and likely 
to classify the condition correctly. 
 
- Explicitly reported that the ACE was independent of the 
reference standard and interpreted without knowledge of it.   
 
- Appropriate statistics used (Sensitivity, specificity, LRs, 
PPV and NPV). 
- No detail on participant recruitment or on the expertise of the 
researchers undertaking the research. 
 
- The period between the reference standard and ACE is 
unknown.  
 
- Demographic information on the participants and an 
explanation for any withdrawals from the study not provided. 
 
- More information on selection criteria; execution of the 
reference standard and ACE; and the timescale of the study 
would have been helpful. 
 
Bak et al. 
2005 
14/34 - Selection criteria and participant recruitment mentioned. 
 
- Reference standard likely to classify the condition. 
 
- Execution of the ACE described. 
 
- Some demographic information available. 
 
- Participants from a population which required consideration 
in the literature. 
 
- No information on the researchers involved. 
 
- It is unknown whether the reference standard was independent 
of the ACE. 
 
-  No report of whether the ACE was interpreted with or without 
knowledge of the reference standard. 
 
- No information on the period of time between the reference 
standard and the ACE and on the study timescale. 
 
- No report of study withdrawals. 
 
- Further information would have been helpful on: the selection 
criteria; participant recruitment; execution of the reference 
standard; and demographic information.   
Mioshi et al. 
2006 
23/34 - A range of different participant groups were included. 
 
- Clear selection criteria and participant recruitment 
information. 
- No report of the researchers involved. 
 
-  No report of whether the ACE was interpreted with or without 
knowledge of the reference standard. 
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- Reference standard likely to classify the condition and 
period between it and the ACE-R seems reasonably short. 
 
- Timescale of study reported. 
 
- Demographic information provided. 
 
- Statistics used seem appropriate. 
 
- Study withdrawals are not mentioned. 
 
- More information on the execution of the reference standard 
and ACE-R and demographic information would have been 
helpful. 
 
- The MMSE was used as part of the reference standard 
assessment. 
Larner 
2007b  
13/34 - Involves a spectrum of participants representative of clinical 
practice. 
  
- Details of different diagnoses given post assessment 
provided. 
 
- Provides selection criteria and participant recruitment 
information. 
 
- Statistics used seem appropriate. 
 
  
- No information on the researchers involved. 
 
- No report given of the execution, independence and blinding of 
the ACE from the reference standard and vice versa. 
 
- Withdrawals from the study are not mentioned. 
  
- The study time scale was not reported.   
 
-  No report of whether the ACE was interpreted with or without 
knowledge of the reference standard. 
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Table 4: Diagnostic Accuracy Information  
 
Study ACE or 
ACE-R 
Cut off 
score 
Sensitivity Specificity Likelihood 
Ratio + 
Likelihood 
Ratio - 
Positive 
Predictive value 
for base rate of 
1.3% 
Negative 
Predictive value 
for base rate  of 
1.3% 
Post test 
probability 
with base rate 
of 1.3% 
Positive 
Predictive 
value for base 
rate of 54% 
Negative 
Predictive 
value for base 
rate of 54% 
Post test 
probability 
with base rate 
of 54% 
Mathuranath
et al. 2000  
ACE 88 0.93 0.71 3.21 0.10 0.04 1.00 0.04 0.79 0.90 0.79 
Larner 2007a ACE 88 1.00 0.43 1.75 0 0.02 1.00 0.02 0.67 1.00 0.67 
Dudas et al. 
2005 
ACE 88 0.93 0.82 5.17 0.09 0.06 1.00 0.06 0.86 0.91 0.856 
Mioshi et al. 
2006 
ACE-R 88 0.94 0.89 8.55 0.07 0.10 1.00 0.10 0.91 0.93 0.91 
Larner 2007b ACE-R 88 1.00 0.48 1.92 0 0.69 1.00 0.02 0.02 1 0.69 
Mathuranath 
et al. 2000 
ACE 83 0.82 0.96 20.50 0.19 0.21 1.00 0.21 0.96 0.82 0.96 
Larner 2007a ACE 83 0.96 0.63 2.59 0.06 0.03 1.00 0.03 0.75 0.93 0.75 
Reyes et al. 
2009 
ACE 83 0.92 0.91 10.22 0.09 0.12 1.00 0.12 0.92 0.91 0.92 
Mioshi et al. 
2006 
ACE-R 82 0.84 1.00 N/A* 0.16 1 1.00 N/A* 1 0.84 N/A* 
Larner 2007b ACE-R 82 0.96 0.72 3.43 0.06 0.04 1.00 0.04 0.80 0.94 0.80 
Larner 2007a ACE 75 0.85 0.83 5.00 0.18 0.06 1.00 0.06 0.85 0.82 0.85 
Larner 2007b ACE-R 75 0.91 0.91 10.11 0.10 0.12 1.00 0.12 0.92 0.90 0.92 
 
* Unable to calculate value because equation involved a denominator of 0 
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Abstract 
 
Objectives 
The Addenbrooke's Cognitive Examination – Revised (ACE-R) is a dementia screening 
tool.  The objectives of this study were to investigate rater accuracy in scoring the ACE-R 
in terms of its total and subscale scores and to examine whether scoring accuracy is 
affected by participant experience of using the ACE-R.   
Methods 
Three filmed vignettes of the ACE-R being administered to older adult actors (mock 
patients) were used to assess scoring accuracy across multiple raters.  The vignettes had a 
pre-determined ‘true score’.  Study participants were required to complete ACE-R scoring 
sheets for each vignette.  Participants were Community Nurses and Trainee Clinical 
Psychologists.   
Results 
Participant scores were compared with the pre-determined true scores as a means of 
measuring scoring accuracy.  The results indicated that the majority of participant scores 
were either the same as or within a few points of the true scores.  However, when 
compared to the true scores, participant total scores differed significantly on two out of 
the three vignettes.  Scoring accuracy was lowest for the Memory subscale of the ACE-R.  
Scoring accuracy issues were also identified for the Visuospatial and Attention and 
orientation subscales.  Individual items which had low scoring accuracy were identified. 
Discussion 
The majority of participants scored the same as or within a few points of the true scores, 
such deviation is likely to be clinically acceptable, providing over-emphasis is not placed 
on cut off scores.  Professionals using the ACE-R should ensure they are familiar with the 
scoring guidelines for the items highlighted in this study as having low scoring accuracy. 
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Introduction 
Dementia refers to global cognitive decline, characteristic of progressive conditions such 
as Alzheimer’s disease (Hannay et al., 2004).  There is a general consensus that early 
dementia diagnosis is desirable because it enables earlier intervention and gives “people 
the opportunity to make choices and plan for the future while they are still relatively well” 
(The National Audit Office, 2007, p.43).  Early diagnosis necessarily requires accurate 
assessment. 
 
The role of cognitive screening in dementia diagnosis 
The National Institute for Health and Clinical Excellence (NICE, 2006) states that a 
dementia diagnosis should only be made following a comprehensive assessment 
involving history taking, cognitive, mental and physical examination and medication 
review.  Cognitive assessment tools are well established aids in this diagnostic process.  
In an older adult population cognitive assessment is typically used for three reasons: i) 
screening for cognitive impairment; ii) differential diagnosis; iii) rating disease severity or 
monitoring disease progression (Woodford and George, 2007).  In clinical practice, where 
time constraints are omnipresent, the possibility of achieving an objective, quantitative 
measure of cognitive functioning following a short administration period is highly 
desirable.  This may explain why, in the arena of cognitive assessment, recent decades 
have witnessed the development of various dementia screening tools to aid the diagnostic 
process.   
 
The fundamental aim of any cognitive screening tool is to infer from the patient's score, 
compared to reference norms, the likelihood that genuine cognitive impairment is present. 
The success of such instruments in achieving this aim depends upon their psychometric 
properties (Cullen et al., 2007).  The time pressures associated with everyday clinical 
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practice mean that screening tools must be brief and easy to administer.  The ideal screen 
should also provide rich qualitative data; enabling a symptom orientated approach to 
assessment, which may aid differential diagnosis of different forms of dementia and 
facilitate better, targeted rehabilitation efforts (Cullen et al., 2007).  A central feature of 
most screening tools is the ‘cut-off ’: the point at which scores move from being regarded 
as normal to abnormal (impaired), thus indicating the presence of the condition of interest 
(i.e. dementia).  It is unlikely there will ever be a cognitive screening tool which will 
always, accurately make this distinction (Hannay and Lezak, 2004).  A recent review 
concluded that useful dementia screening tools should:  
 
“...have good sensitivity and specificity for all dementia types in unselected populations, 
and... elicit information about key cognitive abilities, which can then be compared with 
neuropsychological profiles in different types of dementia” (Cullen et al., 2007, p.9).  
 
Currently a universally accepted, standardized screening tool for dementia remains 
elusive (Gifford and Cummings, 1999).   
 
Measurement issues in cognitive screening tools 
It is generally agreed that the measurement obtained from any instrument is a 
combination of the 'true score' and a degree of measurement error (McDowell, 2006).  
The fundamental difficulty across all cognitive measures is that the true score is never 
precisely known; it can only be inferred from the value obtained (Trochim, 2006).  It is 
essential that cognitive tools minimise the degree of measurement error they create: thus 
making the value they obtain as accurate a reflection of the underlying true score as 
possible.  Measurement errors can be categorised into random errors and systematic 
errors.  Random errors increase group variability but do not affect the average 
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performance (overall mean) of the group.  Systematic errors tend to be consistently either 
positive or negative and thus are considered a source of bias (Trochim, 2006).   
 
There are numerous sources of potential measurement error, which can affect the 
reliability of a cognitive tool. These may be broadly conceptualised into three categories: 
i) client factors, e.g. client motivation, attention, and mood; ii) contextual factors, e.g. 
setting in time and place; iii) rater factors, e.g. administration and scoring issues.   
 
Reliability refers to a measurements consistency.  Inter-rater reliability assesses whether 
the tool is administered and scored consistently between raters (Trochim, 2006).  
Traditionally inter-rater reliability has been investigated by assessing agreement between 
a few (typically expert) raters across numerous trials.  Such designs assume that high 
agreement indicates strong inter-rater accuracy for both administration and scoring.  
However, these designs fail to investigate administration and scoring accuracy across 
multiple raters in a clinical setting.  Furthermore, by considering administration and 
scoring collectively these designs may fail to detect important aspects of each.   
 
Inter-rater reliability studies may benefit from using greater numbers of raters; 
investigating administration and scoring separately; and considering scoring accuracy 
rather than agreement between raters, since raters may show high agreement, but both 
have low accuracy.  If a tool is not consistently administered and scored by different raters 
then its clinical utility is limited.  Therefore the consistency with which a tool is 
administered and scored by a range of professionals is a relevant, yet infrequently 
reported, part of assessing a tool’s generalizability.  A recent study involving multiple 
raters scoring filmed vignettes of two brief screening tools reported that the percentage of 
correct total scores obtained was lower than anticipated (Queally et al., 2010).  These 
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results raise concerns about the lack of attention given to this issue in the literature and 
highlights that test developers need to consider the implications of scoring inaccuracy and 
make recommendations in light of these (Queally et al., 2010). 
 
The ACE-R as a dementia screening tool 
The Addenbrooke's Cognitive Examination (ACE) was originally designed to detect mild 
dementia and differentiate Alzheimer’s disease from Fronto-temporal dementia 
(Mathuranath et al., 2000).  It was revised in 2006, to produce the ACE-R (Mioshi et al., 
2006).  The ACE-R has five subscales: Attention and orientation, Language, Fluency, 
Memory and Visuospatial; each representing a cognitive domain.  The subscale scores are 
summed to produce an overall total score (maximum 100 points).  The Mini Mental State 
Examination (MMSE) is incorporated within the ACE-R.  There are three versions of the 
ACE-R available, to reduce practice effects with repeat testing. 
 
In 2006 the tool was recommended by the Scottish Intercollegiate Guidelines Network, 
(SIGN 86), as a means of improving initial cognitive testing for dementia.  The ACE-R 
has been translated into 15 languages (Bak and Mioshi, 2007) indicating that its clinical 
use internationally is becoming increasingly pervasive.   
 
ACE-R reliability 
The original ACE study suggested that inter-rater reliability of the ACE was likely to be 
high since the tool measured cognition in an objective way; however, this study did not 
formally assess inter-rater reliability and acknowledged that this would be a useful focus 
for future research (Mathuranath et al., 2000).  The ACE-R was reported to have 
undergone “design changes to make the test easier to administer” (Mioshi et al., 2006, 
p.1078).  Nonetheless there are no published data examining the ACE-R’s rater reliability. 
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The current study 
A procedure was developed to investigate rater scoring accuracy on the ACE-R, whilst 
administration was kept constant.  Several items in the ACE-R require a degree of rater 
interpretation.  Based on anecdotal evidence from Older Adult Clinical Psychologists, it 
was hypothesised that professionals may sometimes give clients “the benefit of the 
doubt”, when scoring screening tools.  This can inflate the 'test score' from the 'true score', 
potentially generating conclusions that do not accurately reflect the underlying true score.  
Such over-scoring may lead to systematic measurement errors.  In terms of the ACE-R it 
was hypothesised that the subscales which involve more subjective scoring judgements 
(namely the Visuospatial and Language subscales) would be the ones which would be 
over-scored by professionals. 
 
Furthermore, it may be hypothesised that if individuals do not frequently refer to the 
ACE-R administration and scoring guide they may develop their own unique scoring 
methods.  Thus scoring accuracy may also be affected by rater experience of the ACE-R.   
 
Objectives  
The primary objective was to investigate how accurately the ACE-R is scored by multiple 
raters with a focus on examining whether participants over-score the ACE-R.  Variation of 
scoring accuracy across ACE-R subscales and degree of ACE-R experience were 
investigated as secondary objectives.   
 
Primary hypothesis: 
Participant ACE-R total scores will differ significantly from the ACE-R true scores 
because participants will over score the ACE-R. 
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Secondary hypotheses: 
a) Participant scores on the ACE-R subscales that involve more subjective judgements 
(Visuospatial and Language) will significantly differ from the 'true' subscale scores 
because participants will over score them.  
b) Scoring accuracy will be related to participant experience using the ACE-R. 
 
Method 
 
Participants 
Participants were recruited from two groups of professionals: 
i) Community nurses (CNs) working in older adult community mental health teams, who 
use the ACE-R routinely in their clinical practice.   
ii) Trainee Clinical Psychologists (TCPs) currently completing their Doctorate in Clinical 
Psychology who have used the ACE-R whilst on clinical placement. 
 
Eligibility criteria 
Participants were included if they had administered and scored the ACE-R independently 
in clinical practice on at least one older adult patient.  Participants were excluded if they 
had not used the ACE-R in clinical practice; that is they had not completed it with an 
older adult patient.  Some CN participants had previously received a training session on 
how to administer and score the ACE-R.     
 
Justification of sample size 
The sample size required was based on a power calculation for a one sample t-test, as this 
was the planned main method for statistical analysis.  Since there have been no previously 
published studies on the ACE-R's rater reliability there was no data available to base the 
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power calculation upon.  It was considered that a small effect size would translate into 
only a few points variation from the true score which would not threaten the accuracy of 
the overall conclusions drawn from the ACE-R in clinical practice.  By contrast a medium 
effect size would translate into a difference significantly large enough that it could alter 
interpretation of the ACE-R results, which could in turn, influence a wider assessment 
process.  Therefore the power calculation determined the number of participants 
necessary to detect a medium effect size, using the conservative values of: p-value 0.05 
and power 0.8.  When these values for a one sample t-test were entered into G*Power 
3.010 (Faul et al., 2007, from www.psycho.uni-duesseldorf.de/abteilungen/aap/gpower3/) 
the results indicated that a minimum of 34 participants would be required.   
 
It was hypothesised that both participant sub-groups would over-score the ACE-R; no 
significant difference was expected between the participant groups.  However, to ensure 
power would not be affected if the groups were significantly different, the study aimed to 
recruit a minimum of 34 participants from each of the participant groups. 
 
Measures 
The Addenbrooke's Cognitive Examination – Revised (ACE-R) was the primary outcome 
measure.   
 
Design procedure 
Three filmed vignettes of the principal researcher administering the ACE-R to older adult 
actors (mock patients) were devised (one for each version of the ACE-R).  Vignettes had 
pre-determined ‘true scores’ to allow scoring consistency to be investigated separately 
from administration consistency.  Scripts for these research vignettes were developed by 
an advisory group of Clinical Psychologists with extensive neuropsychological 
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experience within older adult services; the scripts were not based on individual clients.  
Each vignette script was designed to represent a cognitive and clinical profile typical of 
clinical presentation at a memory clinic.  The script for Vignette 1 was designed to be 
reflective of early-stage Alzheimer’s disease (with a true total score of 75); Vignette 2’s 
script was representative of Fronto-temporal dementia, behavioural-variant (true total 
score 84); and Vignette 3 was scripted for affective disorder (true total score 85).  There 
was 100% agreement and accuracy with the true scores, across all the vignettes, when two 
experienced Clinical Psychologists rated them.  The University of Glasgow media 
services filmed and produced the vignettes.  Professional actors were recruited through 
the NHS Role play coordinator; they were given information on the purpose of the study 
and how their performances would be used.  Signed consent was obtained from each of 
the actors (Appendix 2.1).  Each actor performed one vignette, having learned the script 
beforehand.  The actors were paid for their time and were not patients of any relevant 
service.  The researcher who was filmed administering the ACE-R was the same person 
who showed the vignettes to the study participants.  However, this researcher was blind to 
the ‘true scores’ until data collection was completed. 
 
Research procedure 
Potential participants were invited to participate in the study either via email or verbally. 
Participants who opted in to the study attended one of several group sessions, which 
lasted on average 1hour30min.  Each participant received an information sheet about the 
study (Appendix 2.2).  Written consent was obtained from all participants prior to the 
study commencing (Appendix 2.3).  Participation involved completing ACE-R scoring 
sheets in conjunction with watching the vignettes.  Participants viewed each vignette in its 
entirety once and were not permitted to pause or rewind the vignettes, reflecting actual 
clinical practice.  Vignettes were viewed on a projector screen and shown to participants 
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in groups (with a minimum of three participants in each group).  All participants viewed 
the vignettes in the same order (1, 2, 3).  After watching each vignette participants were 
permitted time to complete their scoring of the corresponding ACE-R form.  The ACE-R 
administration and scoring guide was available to participants, on request.  In addition to 
scoring the vignettes the participants completed an additional information form detailing 
their profession and ACE-R experience (Appendix 2.4). A standardised set of instructions 
was read aloud to each group of participants before they commenced participation in the 
study (Appendix 2.5).  Participants were also given the correct orientation information 
(date and place) for each vignette (Appendix 2.6). 
 
Ethical approval 
Prior to the study commencing, ethical approval was gained from a Local Research Ethics 
Committee (Appendix 2.7) and practice was informed by The British Psychological 
Society Code of Ethics & Conduct (2009). 
 
Data analysis 
Statistical analyses were carried out using SPSS and Microsoft Excel.   
 
Results 
 
Fifty-seven participants took part in the study; 45 Community Nurses and 12 Trainee 
Clinical Psychologists.  All participants completed the three vignettes, with the exception 
of one participant who only completed two due to clinical time constraints (this 
participant did not complete Vignette 3).  Four participants did not complete the 
Additional Information sheet.  Across the vignettes the majority of participants scored all 
items; however, some participants did not sum items to provide subscale and total scores 
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(information was missing for 10 participants in Vignettes 1 and 2, and 11 in Vignette 3).   
Although the principal researcher could have summed up missing total and subscale 
scores on participant ACE-R forms, given that the principle focus of the study was on 
scoring reliability, this was not done.  If participants had not fully completed their ACE-R 
forms the missing information was treated as missing data and excluded from relevant 
analyses. 
 
Preliminary analysis   
Initial analysis was undertaken to investigate whether the data set was normally 
distributed.  The Shapiro-Wilks test was undertaken for the participant total and subscale 
scores for each of the vignettes.  The null hypothesis of the Shapiro-Wilks test is that data 
are normally distributed.  The null hypothesis was rejected, across the vignettes, for total 
and subscale scores; this suggests that the data were not normally distributed.  
Furthermore, the skewness and kurtosis of the distribution of total and subscale scores for 
each of the three vignettes indicated that the data may not be normally distributed; the 
kurtosis results were all positive indicating a leptokurtic distribution (an acute peak 
around the mean).  Since the tests for normality indicated that the data did not have a 
normal distribution, further analysis used non-parametric tests. 
 
The Non-parametric Independent-Samples Mann-Whitney U Test was used to examine if 
a significant difference existed between CNs and TCPs total scores on each vignette.  The 
null hypothesis of this test is that the distribution of scores is the same across different 
groups.  The null hypothesis could not be rejected for Vignettes 2 and 3 (U=248.50, 
p=0.96 and U=196.0, p=0.655, respectively) but was rejected for Vignette 1 (U=341.5, 
p=0.039).  When the TCP and CN groups were compared using Independent-Samples 
Mann-Whitney U Tests for each of the Vignette 1 subscales, the Memory subscale was the 
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only one where a significant difference was obtained between the two groups.  Since the 
TCP sample size was small and there was not a significant group difference in Vignettes 2 
and 3 it was decided to combine the two participant groups for further analysis across the 
three vignettes.   
 
Summary of total score results 
Examination of Vignette 1 showed 15% of participant total scores matched the total ‘true’ 
score (TS), while 57% of participant total scores deviated from the TS by 1-2 points.  
Only 9% deviated by 5 or more points.  In Vignette 2, 19% of participant total scores 
matched the TS, 47% deviated by 1-2 points and 21% deviated by 5 or more points.  For 
Vignette 3, 30% of participant total scores matched the TS, 60% deviated by 1-2 points 
and 6% of participant scores were 5 or more points from the TS. 
 
Figure 1 displays the differences between participant total scores and the true total score 
for each vignette.  Visual inspection indicates that the majority of participant scores were 
lower than the TS in Vignette 1 (M=-2.3, SD=4.1).  There was no clear pattern of under or 
over-scoring in Vignette 2 (M=-1.22, SD=4.1) and deviation from the TS was less 
variable in Vignette 3 (M=-0.9, SD=1.9). 
 
INSERT FIGURE 1 HERE 
 
Primary hypothesis: participant ACE-R total scores will differ significantly from the 
ACE-R true scores (TS) because participants will over score the ACE-R. 
To investigate the primary hypothesis, one-tailed, one sample Wilcoxon signed ranks tests 
were undertaken (the results of which are available in Table 1).  The tests were one tailed 
because apriori, a specific directional hypothesis (that participants would over score the 
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vignettes) was made.  The null hypothesis was that participant total scores would be the 
same as the TS for each vignette.  The null hypothesis was rejected in Vignettes 1 and 3 
but could not be rejected in Vignette 2.  These results indicate that the primary hypothesis 
was partially supported in Vignettes 1 and 3, with participant scores differing significantly 
from the TS.  The medians for the participant total scores in Vignettes 1 and 3 were below 
the TS indicating that over-scoring was not occurring. 
 
INSERT TABLE 1 HERE 
 
Secondary hypothesis a) participant scores on the ACE-R subscales which involve 
more subjective judgements (Visuospatial and Language) will significantly differ 
from 'true' subscale scores because participants will over score them.  
One tailed, one sample Wilcoxon signed ranks tests were used to investigate this 
hypothesis (see Table 1).  The tests were one tailed because apriori, a specific directional 
hypothesis (that participants would over score these subscales) was made.  The null 
hypothesis was that participant scores would be the same as the TS for both the Language 
and Visuospatial subscales.  The null hypothesis was retained for the Language subscale 
in Vignettes 1 and 2, but rejected in Vignette 3.  Whilst the null hypothesis was rejected 
for the Visuospatial subscale in Vignettes 2 and 3, but not for Vignette 1.  These results 
indicate partial support for secondary hypothesis a), with significant differences between 
participant scores and the TS found for the Language subscale in Vignette 3 and the 
Visuospatial subscale in Vignettes 2 and 3. 
  
Figure 2 shows participant subscale scores in comparison to subscale TS for all three 
vignettes.  Visual inspection indicates a trend of slight over-scoring on the Visuospatial 
subscale and no clear pattern of over or under-scoring on the Language subscale.   
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INSERT FIGURE 2 HERE 
 
Additional analysis 
Inspection of Figure 2 reveals that the majority of participant scores are lower than the TS 
on the Memory subscale and there is also a trend towards under-scoring on the Attention 
and orientation subscale.  To investigate whether significant differences exist between 
participant scores and TS on the subscales of Attention and orientation, Memory and 
Fluency, two tailed one sample Wilcoxon signed ranks tests were undertaken (Table 1).  
These tests were two tailed because predictions had not been made about how participants 
would score these subscales. The null hypothesis of these tests was that participant 
subscale scores would be the same as the subscale true scores. 
 
For the Attention and orientation subscale a significant difference was found between 
participant scores and TS in Vignettes 1 and 3 but not 2.  For the Memory subscale the 
null hypothesis was rejected in Vignettes 1, 2 and 3; highlighting that participant scores 
significantly differ from the TS across all three Memory subscales.  In comparison, for the 
Fluency subscale it was not possible to reject the null hypothesis in Vignettes 1, 2 and 3; 
this suggests there was no evidence of a significant difference found between participant 
scores and the TS for all three Fluency subscales.  
 
Item level analysis 
To examine how participant scores differed from the TS at the level of individual items, 
Table 2 was generated.  The table shows, for every item and subscale in Vignettes 1, 2 and 
3, the percentage of participant scores which were: the same as the TS; plus or minus 2 
points from the TS; or plus or minus 3 or more points from the TS.  
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INSERT TABLE 2 HERE 
 
Across all three vignettes the items where most participant scores deviated from the TS 
were:  
• Orientation questions in the Attention and orientation subscale (23%).  
• Naming item in the Language subscale (23%).  
• Name and address recall (25%) and recognition (28%) questions in the Memory 
subscale. 
• Clock item in the Visuospatial subscale (45%).   
The percentages in brackets above represent the total deviation from the true score for 
each item across all three vignettes. 
 
Secondary hypothesis b) scoring accuracy will be related to participant experience 
using the ACE-R. 
The non-parametric Independent-Samples Mann-Whitney U Test was used to address this 
hypothesis.  The null hypothesis was that for groups of participants with varying levels of 
ACE-R experience their total scores would be equal. The participants were divided into 
different groups as follows: 
i) Participants who attended a one off training session on the ACE-R (n=31) and 
 those who did not (n=21). 
ii) Participants who utilised the ACE-R scoring and administration guide during their 
participation in the study (n=24) and those who did not (n=33). 
iii) Participants who reported using the ACE-R in their clinical practice anywhere 
between once a week to once a month (n=25) and those who reported using the 
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ACE-R anywhere between once every three months to less than once every six 
months (n=27). 
iv) Participants who reported their last use of the ACE-R as being up to a week to up 
to one month prior to the study (n=31) and those who reported their last use of the 
ACE-R as being more than a month to more than six months prior to the study 
(n=22). 
The Independent-Samples Mann-Whitney U Test was completed separately for each of 
the above (i-iv), per vignette (output available in Table 3).  The null hypotheses were 
retained for each of the above, across all three vignettes.  This suggests that participant 
experience of the ACE-R did not lead to significant differences in participant 
performance.  However, some of the sub-groups of participants in the analysis had small 
numbers, thus these conclusions should be interpreted with caution.   
 
INSERT TABLE 3 HERE 
 
Calculation errors 
It was discovered that some of the subscale and overall total scores reported on 
participant ACE-R forms differed from the summed total of recorded items.  This 
suggests that calculation errors were being made in the ‘summing up’ of items to obtain 
subscale and overall total scores.  In Vignette 1, based on the total score, 26% of 
participants made a ‘summing up’ error; in Vignette 2, 40% of participants made this 
error; and in Vignette 3 it was 18%.  In Vignette 2 the majority of participants made the 
same calculation error, they failed to include the Name and address recognition item in 
their total score.    
 
Discussion 
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Despite the fact that some significant differences have been obtained in this study, overall 
the majority of participant scores were either the same as, or within one or two points of 
the true scores at both total and subscale levels.  It is probable that such a discrepancy will 
be acceptable in clinical practice.  Nonetheless, if emphasis is placed on fixed cut-off 
scores then even a few points of variation could have significant clinical implications; 
however, since the ACE-R is a screening tool its results should not be used in such a 
definitive manner.   
 
Total scores 
The majority of participants either rated vignette performance as the true score or within a 
few points of the true score for both the total and subscale scores across all three of the 
vignettes.  In terms of the hypothesis that, due to participant over-scoring, participant total 
scores would be significantly different from true total scores, the results indicated that 
over-scoring did not systematically occur.  In Vignettes 1 and 3 there was a significant 
difference between participant and true total scores, but results indicated that participants 
were under-scoring the ACE-R.  In Vignette 2 participant variance from the true score did 
not occur in a systematic way.  It may be that there was greater scope for under-scoring 
because there is a maximum amount of points per ACE-R item so when items are correct 
they cannot be over-scored, but may still be under-scored.  In addition, participants may 
have been more cautious when scoring the vignettes in this research project than they are 
in clinical practice.  They may also have been less likely to give the mock patients in the 
vignettes the ‘benefit of the doubt’ because they had not directly administered the ACE-R 
to them.   
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The significant differences between participant scores compared to true scores for the 
totals of Vignettes 1 and 3 had large effect sizes.  The true total score for Vignette 1 was 
75; in comparison the true total score for Vignette 3 was 85.  Both vignettes indicated a 
degree of under-scoring; however, there was less variance in participant scores for 
Vignette 3 compared to Vignette 1.  This suggests that scoring accuracy may be poorer 
when patient true scores involve more errors.  This is concerning for clinical practice as 
the majority of participants who present to services for dementia screening are likely to 
present with some degree of cognitive impairment.  If patient performance on the ACE-R 
is under-scored in clinical practice this may lead to false positive results on the tool, 
which may cause unnecessary distress and worry.   
 
Subscales 
Particular ACE-R subscales were associated with less scoring accuracy across the 
vignettes.  Although the present study hypothesised that this would be found within more 
subjective subscales such as Language and Visuospatial, it was the Memory subscale that 
had the least accuracy.  It was the only one where there was a significant difference 
between participant scores and the true score across all three vignettes.  This is an 
interesting finding given that the Memory subscale contributes 26% to the weighted ACE-
R total score and memory difficulties are commonly found in the intended patient 
population.     
  
There was no significant difference found in the Fluency subscale across all of the 
vignettes.  However in Vignette 2, 40% of participants did not identify the true Fluency 
scores, this may be reflective of the perseveration of words (e.g. pig and piggies) that 
occurred on the fluency items in Vignette 2, but not Vignettes 1 and 3.  The scoring 
guidelines state that perseverations should not count toward the total of correct responses.  
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The Vignette 2 Fluency results indicate that notable numbers of participants were 
counting the perseveration responses; this suggests that participants were not aware of the 
finer details involved in scoring this subscale. 
 
Individual items 
There were certain ACE-R individual items found to have lower scoring accuracy across 
vignettes.  In particular the Name and Address recall and recognition items of the 
Memory subscale were frequently scored inaccurately, this may indicate that the 
participants were not aware of the scoring instructions for these items.  In Vignette 2 the 
filmed mock patient correctly recalled all the information in the recall item and so was not 
administered the recognition item; however, according to the ACE-R scoring guidelines, 
full marks for the recognition item should have been automatically rewarded.  Several 
participants awarded no points for the recognition item; this may indicate that many 
participants were not aware of this scoring rule.  Since the recognition item is weighted 5 
points, omitting it can cause substantial deviation from the true score.  Incorporating the 
guidelines for scoring the Name and address recall and recognition items into the ACE-R 
scoring sheet, instead of them being in the separate administration and scoring guidelines 
document, may reduce the likelihood of these scoring errors.   
 
The clock item on the Visuospatial subscale was another item which had poorer scoring 
accuracy, this is one of the most subjective items and participants may not have been 
aware of the rules for assigning points according to the clock face, numbers and hands as 
outlined in the ACE-R scoring guide.  The Naming item in the Language subscale was 
also identified as being scored with lower accuracy.  This item has a maximum of ten 
points and involves the patient being required to name ten line drawings.  It may be that 
participants differed in what they considered to be acceptable answers, which may also be 
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the case for the orientation questions which had a lower level of accuracy associated with 
them.  It might be beneficial to have more detailed information on acceptable responses 
for these items available in the ACE-R administration and scoring guidelines.  
 
In the current study 33 out of the 57 participants did not request a copy of the 
administration and scoring guidelines whilst scoring up their forms, indicating that 
guidelines may not be routinely referred to in clinical practice.  Instead of increasing 
detail in the scoring guidelines, it may be more beneficial if the ACE-R scoring forms 
were adapted to incorporate more detailed scoring information for items identified as 
having poorer accuracy.  This may minimise scoring errors and thus increase scoring 
accuracy. 
 
The study identified that a significant number of participants made errors when summing 
up their item scores to give the total score, it may be that because the ACE-R is scored out 
of 100 this increases the likelihood of making such a human calculation error.   
 
Limitations of current study 
The study involved investigation of several hypotheses (and therefore multiple 
comparisons).  Given that the majority of these were specific apriori hypotheses and that 
identifying significant differences between participant scores and true scores (or between 
experience variables and scoring accuracy) would potentially have important implications 
for clinical practice, it was felt that any correction for multiple comparisons (e.g. 
Bonferroni correction) would be too conservative and inflate the likelihood of a Type II 
error (Perneger, 1998). Nonetheless, not undertaking any correction for multiple 
comparisons may have increased the chance of a Type I error in the results. 
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The one sample Wilcoxon signed ranks tests aimed to identify if the participants were 
systematically scoring in a particular direction (i.e. over-scoring) which was significantly 
different from the true score.  Using this test it is not possible to conclude from a non-
significant result that the participant scores showed a high level of accuracy when 
compared to the true scores because a high scatter of differences may lead to a non-
significant result when there is actually low accuracy (Altman, 1991).  This is evidenced 
when Vignette 3 and Vignette 2 total scores are compared.  It is clear that participant 
scores show greater variance from the true score in Vignette 2 than Vignette 3.  In 
Vignette 3 many participant scores are slightly below the true score so the Wilcoxon 
reports a significant difference.  In comparison, because the variance in Vignette 2 is on 
either side of the true score the Wilcoxon reports a non-significant result.  It has been 
recommended that, when comparing two methods of measurement, (in this study this 
would translate to comparing the participant scores and the fixed true scores) the 
differences between them should be plotted in a graph and their mean differences and 
standard deviations obtained (Altman, 1991).  However, the interpretation of these means 
and standard deviations must depend on clinical circumstances; it is not possible to use 
statistics to define acceptable agreement in such cases (Altman, 1991).  Therefore, in this 
study, the limits of how many points deviation from the true score are clinically 
acceptable cannot be answered statistically.  As a result, the conclusion that a few points 
deviation is likely to be clinically acceptable is based on expert opinion rather than 
statistical assessment.   
 
The power calculation recommended a minimum sample of 34 participants.  Whilst the 
study recruited 57 participants the participant group contained more CNs (45) than TCPs 
(12).  It had been hoped that it would be possible to recruit 34 participants for each of the 
professional groups.  Unfortunately several TCPs had only observed the ACE-R being 
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used in clinical practice and therefore did not meet inclusion criteria.  There was a 
significant difference between the two groups in Vignette 1, but not in Vignettes 2 and 3; 
the decision was therefore made to combine the groups.  However, there may be 
significant differences between these two professional groups in terms of their ACE-R 
scoring accuracy which, due to the small TCP sample size, this study was unable to 
reliably detect.  In addition, the current study did not identify significant differences in 
scoring accuracy as a result of experience with the ACE-R.  Again, the numbers in the 
participant groups involved in these analyses may have been too small to detect 
significant effects.   
 
Furthermore, not all participants summed up the ACE-R items to obtain subscale and total 
scores; this meant there was some missing information which may have impacted on the 
analysis.  The likelihood of this is reduced by the fact that the minimum sample size was 
never violated.  
 
This study used a design which enabled scoring accuracy to be explored, independent of 
test administration, for multiple raters.  Part of the design involved devising a set of ‘true’ 
scores for each of the vignettes.  It is possible that the true scores included a degree of 
error; however, the likelihood of this was minimised by scripting the vignettes.  In 
addition, the 100% accuracy and agreement that was obtained when the vignettes were 
scored by two experienced Clinical Psychologists suggests that the defined true scores 
were an accurate reflection of actual true scores. 
 
Potential areas for future research 
In future it would be useful if this study could be replicated using a larger participant 
sample.  Future replications of the study would benefit from recruiting larger participant 
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sub-groups to enable more comprehensive assessment of potential scoring accuracy 
differences between professional groups and between individuals with varying levels of 
ACE-R experience. 
 
This study exclusively investigated multiple rater scoring accuracy on the ACE-R, 
however scoring accuracy is only one element of inter-rater reliability, how the tool is 
administered by multiple raters should be addressed in future research.  In addition 
research exploring the intra-rater reliability (test re-test) of the ACE-R would make a 
valuable contribution to the ACE-R literature. 
 
It has been suggested that scoring accuracy on screening tools might be increased by 
using filmed vignettes as interactive training exercises (Queally et al., 2010).  This 
suggests that the design used in this study could be adapted in future research.  Using the 
vignettes of mock patients is an ethical means of generating a realistic clinical scenario 
which researchers are able to manipulate according to their objectives.   
 
Conclusion 
 
Results indicate that the ACE-R is a robust tool when scored by multiple raters.  There 
were however significant differences between the participant and true scores across the 
vignettes at both the total and subscale level.  Practitioners should take these findings into 
account in clinical practice and, as a result, be wary about using definitive cut off scores.  
Certain items on the ACE-R were identified across the vignettes as being associated with 
lower scoring accuracy; these items typically required a more subjective level of 
judgement or had a more complex scoring system.  It may be that accuracy could be 
improved if raters familiarised themselves extensively with the scoring guide or more 
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detailed guidance on how to score these items was incorporated into the ACE-R scoring 
sheets.  The vignettes design utilised in this study could be adapted to investigate similar 
issues related to scoring and administration in future. 
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Figure 1: Vignette Total Score 
 
 
 
 
 
 
 
 
 
 
Graph Key 
 Mean Difference 
 True Score 
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Table 1: Summary of one sample Wilcoxon signed rank tests 
 
 
ACE-R 
scores 
Vignette 1 Vignette 2 Vignette 3 
True 
score 
Median One sample Wilcoxon Signed 
Ranks test 
True 
score 
Median One sample Wilcoxon Signed 
Ranks test 
True 
score 
Median One sample Wilcoxon Signed 
Ranks test 
Total 75 73 W(52) = 87.5, z=-4.9, 
p=<0.001, r = 0.67 
84 84 W(52) = 361.50, z=-1.36, 
p=0.09, r = 0.19 
85 84 W(49) = 112.50, z=-3.46, 
p=<0.001, r = 0.49 
Language 22 22 W(47) = 150.50, z=-0.643, 
p=0.26, r = 0.09 
24 24 W(46) = 151.00, z=-0.327, 
p=0.37, r = 0.05 
26 26 W(45) = 0.00, z=-3.71, 
p=<0.001, r = 0.55 
Visuospatial 14 14 W(46) = 41.50, z=-1.40, 
p=0.08, r = 0.20 
12 13 W(47) = 494.50, z=3.51, 
p=<0.001, r = 0.51 
14 15 W(45) = 883.00, z=4.50, 
p=<0.001, r = 0.66 
Attention & 
Orientation 
16 16 W(46) = 100, z=-2.9, 
p=0.004, r = 0.42 
17 17 W(46) = 39.00, z=-0.48, 
p=0.632, r = 0.07 
18 17 W(44) = 0.00, z=-5.67, 
p=<0.001, r = 0.84 
Memory 18 17 W(47) = 0.00, z=-5.5, 
p=<0.001, r = 0.79 
26 26 W(46) = 1.00, z=-3.57, 
p=<0.001, r = 0.52 
19 19 W(44) = 0.00, z=-3.30, 
p=0.001, r = 0.49 
Fluency 5 5 W(46) = 23.50, z=-4.2, 
p=0.67, r = 0.61 
5 5 W(46) = 139.00, z=1.91, 
p=0.057, r = 0.28 
8 8 W(44) = 4.00, z=-0.38, 
p=0.705, r = 0.06 
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Figure 2: Participant differences from true subscale scores 
 
 
 
Key 
Vignette 1:   
Vignette 2:   
Vignette 3:   
*Missing data: 1 Memory outlier of -17 and 1 
Fluency outlier of 16 are excluded from the 
graphs. 
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Table 2: Breakdown of participant scores per question for Vignettes 1, 2 and 3 
    
Attention and 
Orientation 
 
Vignette 1 (%) Vignette 2 (%) Vignette 3 (%) 
True 
Score 
(TS) 
Same 
as TS 
+/- 2 
points 
from TS 
More than 
+/-3 points 
from TS  
True 
Score 
(TS) 
Same 
as TS 
+/- 2 
points 
from TS 
More than 
+/-3 points 
from TS  
True 
Score 
(TS) 
Same 
as TS 
+/- 2 
points 
from TS 
More than 
+/-3 points 
from TS  
Orientation 1                                  3/5 68 32  5/5 100   5/5 100   
Orientation 2 5/5 89 11  4/5 79 21  5/5 25 75  
Registration 3/3 95 5  3/3 100   3/3 100   
Attention & Conc. 5/5 81 17 2 5/5 86 12 2 5/5 98 2  
Subscale Total 16/18 36 53 11 17/18 72 26 2 18/18 27 73  
 
Memory 
 
Vignette 1 (%) Vignette 2 (%) Vignette 3 (%) 
True 
Score 
(TS) 
Same 
as TS 
+/- 2 
points 
from TS 
More than 
+/-3 points 
from TS  
True 
Score 
(TS) 
Same 
as TS 
+/- 2 
points 
from TS 
More than 
+/-3 points 
from TS  
True 
Score 
(TS) 
Same 
as TS 
+/- 2 
points 
from TS 
More than 
+/-3 points 
from TS  
Recall 2/3 100   3/3 98 2  3/3 100   
Anterograde memory 6/7 100   7/7 98 2  6/7 100   
Retrograde memory 2/4 88 12  4/4 98 2  4/4 98 2  
Name&AddressRecall 4/7 28 70 2 7/7 100   1/7 89 11  
Name&AddressRecog 4/5 53 47  5/5 75  25 5/5 95 3 2 
Subscale Total 18/26 21 62 17 26/26 66 2 32 19/26 71 22 7 
 
Fluency 
 
Vignette 1 (%) Vignette 2 (%) Vignette 3 (%) 
True 
Score 
(TS) 
Same 
as TS 
+/- 2 
points 
from TS 
More than 
+/-3 points 
from TS  
True 
Score 
(TS) 
Same 
as TS 
+/- 2 
points 
from TS 
More than 
+/-3 points 
from TS  
True 
Score 
(TS) 
Same 
as TS 
+/- 2 
points 
from TS 
More than 
+/-3 points 
from TS  
Letter fluency 4/7 91 7 2 2/7 60 37 3 3/7 98 2  
Animal fluency 1/7 86 12 2 3/7 72 26 2 5/7 91 9  
Subscale Total 5/14 79 19 2 5/14 60 34 6 8/14 91 7 2 
 
 
 
 
75 
 
 
Language 
 
Vignette 1 (%) Vignette 2 (%) Vignette 3 (%) 
True 
Score 
(TS) 
Same 
as TS 
+/- 2 
points 
from TS 
More than 
+/-3 points 
from TS  
True 
Score 
(TS) 
Same 
as TS 
+/- 2 
points 
from TS 
More than 
+/-3 points 
from TS  
True 
Score 
(TS) 
Same 
as TS 
+/- 2 
points 
from TS 
More than 
+/-3 points 
from TS  
Comprehension 1 1/1 100   1/1 100   1/1 100   
Comprehension 2 3/3 100   3/3 93 7  3/3 98 2  
Writing 1/1 98 2  1/1 98 2  1/1 100   
Repetition 1 2/2 100   2/2 98 2  2/2 100   
Repetition 2 1/1 100   1/1 100   1/1 100   
Repetition 3 0/1 81 19  0/1 96 4  1/1 100   
Pencil/watch naming 2/2 98 2  2/2 100   2/2 100   
Naming  7/10 56 42 2 10/10 96 4  10/10 76 24  
Comprehension 3 4/4 96 4  4/4 91 9  4/4 100   
Reading 1/1 100   0/1 74 26  1/1 100   
Subscale Total 22/26 46 39 14 24/26 47 47 6 26/26 63 30 7 
 
Visuospatial 
 
Vignette 1 (%) Vignette 2 (%) Vignette 3 (%) 
True 
Score 
(TS) 
Same 
as TS 
+/- 2 
points 
from TS 
More than 
+/-3 points 
from TS  
True 
Score 
(TS) 
Same 
as TS 
+/- 2 
points 
from TS 
More than 
+/-3 points 
from TS  
True 
Score 
(TS) 
Same 
as TS 
+/- 2 
points 
from TS 
More than 
+/-3 points 
from TS  
Pentagon 1/1 93 7  1/1 100   1/1 98 2  
Cube 0/2 98 2  0/2 91 9  2/2 98 2  
Clock 5/5 93 2 5 3/5 33 67  4/5 2 98  
Dots 4/4 100   4/4 98 2  3/4 100   
Letters 4/4 96 4  4/4 96 4  4/4 100   
Subscale Total 14/16 66 23 11 12 29 69 2 14/16 2 91 7 
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Table 3: Output for Independent Samples Mann Whitney U Tests 
 
 
Participant 
groups 
Vignette 1 Vignette 2 Vignette 3 
Guide used U=252.5, p=0.083 U=421.0, p=0.169 U=250.5, p=0.312 
Training U=291.0, p=0.983 U=279.0, p=0.821 U=212.5, p=0.231 
How often U=292.5, p=0.895 U=274.5, p=0.607 U=186.0, p=0.077 
Last  use U=301.5, p=0.952 U=294.0, p=0.905 U=193.0, p=0.102 
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Abstract 
 
In this reflective account I apply the Atkins and Murphy (1994) model of reflection to an 
incident which I experienced within a Cognitive Stimulation Therapy Group for people 
with dementia.  Using the model, I identify my initial emotional response within the 
group to a man with dementia, who presented as acutely distressed due to his inability to 
recall important information from his past.  I then go on to consider my emotions in more 
detail, alongside their accompanying thoughts.  From this process I produce some key 
questions about the incident and I draw upon my own knowledge, social beliefs and the 
writings of Terry Pratchett to explore these questions further.  I consider the impact of the 
answers I generate within the wider context of services for people with dementia.  Finally, 
I conclude by reflecting on the model used and my experience of writing the account. 
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Abstract 
 
In this reflective account I apply the Rolfe et al. (2001) Framework of Reflexive Practice 
as a model to guide my reflections triggered by an encounter with a patient while on a 
joint home visit with a learning disability nurse.  Using the Rolfe et al. (2001) model I 
initially detail the situation wherein a patient showed the nurse and I a hernia, which was 
causing him significant levels of discomfort.  I consider my immediate and subsequent 
emotional responses to the incident, before going on to contemplate my thoughts and 
emotions in more detail, drawing upon wider sources of knowledge to assist my reflective 
processes as appropriate.  I then consider the wider service level issues related to my 
reflections.  Finally, I conclude by reflecting on the model used and my experience of 
writing the account. 
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Appendix 1.2: Detailed search strategy 
 
All of the text word searches outlined below were conducted on the databases: Medline, 
EMBASE, PsychINFO, All EBM Reviews.   Each search was limited to the time span 2000-April 
2010 and duplicates were removed. 
 
Search 1 ((ACE?R or Addenbrooke*) and (dement* or alzheimer* or cognitive 
impair*)).tw.  
   
Search 2 (ACE and (dement* or alzheimer* or cognitive impair*) and (scale* or test* or  
  tool* or screen* or assess* or battery or questionnaire*)).tw.  
   
Search 3 (ACE?R or Addenbrooke*) were combined with the  (depressi* or head injur* or 
stroke or brain injur* or cerebrovascular accident* or cerebrovascular incident* 
or TIA or transient isch?emic or scan* or MRI or magnetic resonance or CT or 
compute* tomograph*)).tw.   
   
Search 4 Addenbrooke*.tw. 
   
Search 5 (ACE and (depressi* or head injur* or stroke or brain injur* or 
cerebrovascular accident* or cerebrovascular incident* or TIA or transient 
isch?emic or scan* or MRI or magnetic resonance or CT or compute* 
tomograph*) and (scale* or test* or tool* or screen* or assess* or battery 
or questionnaire*)).tw 
   
Search 6 ((scale* or test* or tool* or screen* or assess* or questionnaire) adj 
(dement* or Alzheimer* or cognitive impair*)).tw  
   
Search 7 Combined searches 3, 4, 5, 6, 7 using ‘OR’ 
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Appendix 1.3: Quality rating checklist 
 
Checklist for Diagnostic Accuracy 
 
 
Study Reference:   _____________________________________________ 
 
 
SCORING: 
2 – information well presented and detailed 
1 – information present but lacks adequate detail 
0 – information absent 
 
Items Score 
Abstract and Introduction  
Abstract provides structured summary of trial design, methods, results, and 
conclusions and identifies article as a study of diagnostic accuracy 
 
Introduction clearly states the research question or study aims 
 
Total for abstract and introduction /4 
Methodology  
The spectrum of participants is representative of the participants who will receive 
the test in practice 
 
Selection criteria are clearly described (inclusion and exclusion) 
 
Participant recruitment explained (ie was recruitment based on presenting 
symptoms, results from previous tests, or the fact that the participants had received 
the index tests or the reference standard?) 
 
Describe the number, training and expertise of the persons executing and reading the 
index tests and the reference standard. 
 
Is the reference standard likely to classify the condition correctly 
 
The period between reference standard and index test is short enough to be 
reasonably sure that the target condition did not change between the two tests.  
 
The reference standard was independent of the index test (i.e. the index test did not 
form part of the reference standard). 
 
The execution of the index test was described in sufficient detail to permit 
replication of the test 
 
The execution of the reference standard was described in sufficient detail to permit 
replication of the test.  
 
Index test results were interpreted without knowledge of the results of the reference 
standard  
 
Total for methodology /20 
Results and Discussion  
An explanation is provided for withdrawals from the study 
 
Report when study was done, including beginning and ending dates of recruitment. 
 
Report clinical and demographic characteristics of the study population. 
 
Describe methods for calculating or comparing measures of diagnostic accuracy, and 
other statistical methods used seem reasonable. 
 
Discussion: Trial limitations are acknowledged and the clinical applicability of the 
study findings are discussed. 
 
Total for Results and Discussion /10 
Grand Total /34 
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Appendix 2.1: Actors consent form  
 
Section of Psychological Medicine 
Gartnavel Royal Hospital 
1055 Great Western Road 
Glasgow 
 
 
 
Consent Form  
 
I consent to the DVD of my performance as an older adult actor completing the 
Addenbrooke’s Cognitive Examination – Revised (ACE-R) being used in the following 
ways: 
 
• To aid the completion of Stephanie Crawford’s (Trainee Clinical Psychologist) 
Major Research Project: A Novel Approach to Investigating the Reliability of the 
Addenbrooke's Cognitive Examination - Revised (ACE-R) 
 
• As part of an ACE-R training package developed by and administered within 
NHS Greater Glasgow and Clyde Healthboard. 
 
• As a means of assisting NHS Greater Glasgow and Clyde professionals to gain a 
better understanding of dementia screening tools. 
 
 
 
 
---------------------------------------               -----------------         -------------------------------- 
Name of Participant           Date      Signature 
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Appendix 2.2: Participant information sheet 
  
Section of Psychological Medicine  
Gartnavel Royal Hospital 
1055 Great Western Road 
Glasgow 
 
 
 
A Novel Approach to Investigating the Reliability of the Addenbrooke's 
Cognitive Examination (ACE-R) 
 
Information Sheet 
10/09/09 (Version 2) 
I would like to invite you to take part in a research study. Before you decide you need to 
understand why the research is being done and what it would involve for you. Please take 
time to read the following information carefully.  If there is anything that is not clear or if 
you would like more information please contact me.  
 
Who is conducting the research? 
The research is being carried out by Stephanie Crawford (Final year Trainee Clinical 
Psychologist), from the Section of Psychological Medicine.  
 
What is the purpose of the study? 
The study aims to explore how different clinical presentations are scored on the 
Addenbrooke's Cognitive Examination - Revised (ACE-R) by professionals working 
within the NHS. 
 
Why have I been invited? 
You have been invited to take part in this study because you have had experience administering 
the Addenbrooke's Cognitive Examination – Revised (ACE-R) clinically. 
 
Do I have to take part? 
It is up to you to decide.  You will be asked to sign a consent form to show you have agreed to 
take part. You are free to withdraw at any time, without giving reason.  
 
What does taking part involve? 
Taking part involves attending a one off session in which you will be shown three filmed vignettes 
of older adult actors being administered the ACE-R.  You will be required to watch each vignette 
in its entirety whilst concurrently scoring an accompanying ACE-R form.  You will also be asked 
to complete an Additional Information sheet detailing your occupation and your experience to 
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date with the ACE-R.  It is anticipated that the session will last no more than 2 hours.  Once the 
study is completed you will receive feedback on the overall group results.  Depending on the 
overall results there may be further one off sessions offered which would discuss in more detail 
the results of the study; you will be invited to attend such follow-up sessions if you wished to. 
 
What happens to the information? 
Your identity and personal information will be completely confidential and known only to the 
researcher and her academic supervisor (Professor Jonathan Evans). The information obtained 
will remain confidential and stored within a locked filing cabinet. The data are held in accordance 
with the Data Protection Act, which means they are kept safely and cannot be revealed to other 
people, without your permission.  
 
What are the possible benefits of taking part? 
It is hoped that by taking part in this research, you will be providing valuable information 
regarding how professionals score the ACE-R in clinical situations.  It is hoped that this 
information will influence further research into how dementia screening tools are utilised by high 
volumes of practitioners. 
 
Who has reviewed the study? 
This study has been reviewed by the NHS Greater Glasgow and Clyde Research Ethics 
Committee 3 and the University of Glasgow. 
 
If you have any further questions? 
You will have a copy of the information sheet and signed consent form to keep. If you would like 
further information about this research project please contact Stephanie Crawford or her clinical 
supervisors Dr Leigh Whitnall and Dr Joanne Robertson.  If you wish to seek general advice 
about participating in this study from someone not closely linked to the study, please contact Dr 
Susan Cross (Consultant Clinical Psychologist).  Please find all contact details overleaf. 
 
Contacts: 
Miss Stephanie Crawford 
Trainee Clinical Psychologist 
Department of Psychological Medicine 
Gartnavel Royal Hospital 
1055 Great Western Road 
G12 0XH 
Tel: 0141 211 0607 
Email: scrawford@nhs.net 
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Dr Joanne Robertson 
Chartered Principal Clinical Psychologist 
Clinical Psychology Stroke Services – Clyde 
Royal Alexandra Hospital 
Corsebar Road 
Paisley 
Tel: 0141 314 6893 
Email: Joanne.Robertson2@nhs.net 
 
Dr Leigh Whitnall 
Chartered Principal Clinical Psychologist 
Cardiac Rehabilitation – Clyde 
Health at Heart Centre 
Royal Alexandra Hospital 
Corsebar Road 
Paisley 
Tel: 0141 314 6852 
Email: leigh.whitnall@nhs.net 
 
Dr Susan Cross 
Consultant Clinical Psychologist 
Unit 8C, The Quadrangle 
59 Ruchill Street 
Glasgow  
G20 9PX 
Tel: 0141 232 0060 
Email: Susan.Cross@ggc.scot.nhs.uk  
 
If you have a complaint about any aspect of the study? 
If you are unhappy about any aspect of the study and wish to make a complaint, please contact the 
researcher in the first instance.  The normal NHS complaint mechanisms are also available to you. 
 
Thank-you for your time and co-operation 
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Appendix 2.3: Participant consent form 
 
 
Section of Psychological Medicine 
Gartnavel Royal Hospital 
1055 Great Western Road 
Glasgow 
 
Subject number: 
 
 
A Novel Approach to Investigating the Reliability of the Addenbrooke's 
Cognitive Examination - Revised (ACE-R) 
 
Consent Form  
   
        Please initial box 
 
I confirm that I have read and understand the information sheet dated  
10/09/09 (Version 2) for the above study and have had the opportunity 
 to ask questions. 
 
 
I understand that my participation is voluntary and that I am free to  
withdraw at any time, without giving any reason.  
 
 
I agree to take part in the above study 
 
 
 
 
---------------------------------------               -----------------         -------------------------------- 
Name of Participant           Date      Signature 
 
 
 
 
 
 
 
1 copy to the participant, 1 copy to the researcher 
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Appendix 2.4 Additional information sheet 
Section of Psychological Medicine 
Gartnavel Royal Hospital 
1055 Great Western Road 
Glasgow 
Subject number: 
 
A Novel Approach to Investigating the Reliability of the Addenbrooke's 
Cognitive Examination (ACE-R) 
 
Additional Information Sheet 
 
Please answer the following questions. 
 
1) What is your occupation and how long have you been in this post? 
 
 ________________________________________________________________ 
 
2) How often do you use the Addenbrooke's Cognitive Examination – Revised 
(ACE-R) in your clinical work? (please circle the most appropriate response). 
 
 once a week     once a fortnight    once a month once every 3 months  
 
 once every 6 months      less than once every 6 months   
 
3 a) Have you attended an ACE-R training course? (please circle) 
 
 Yes      No 
 
   b) If you answered 'No' to question 3 a) please briefly state how you learned to  
 use the ACE-R. 
 
 ________________________________________________________________ 
  
 ________________________________________________________________ 
 
4) Please give an estimate of how long you have used the ACE-R in your clinical 
practice: 
 
 ___________ years and __________ months 
 
5) When was the last time you administered the ACE-R in clinical practice? (please   
 circle the most appropriate response) 
 
 Up to 1 week ago Up to a fortnight ago  Up to 1 month ago 
 
 Over a month but less than 6 months ago  Over 6 months ago 
 
 
 
 
98 
 
Appendix 2.5: Instructions given to participants 
 
Having now read the information sheet, does anyone have any questions? 
 
If you are happy to proceed and participate in this study could you please complete the 
consent forms and the Additional Information sheets that are in your research packs. 
 
During the study you will be shown three vignettes.  In each a version of the ACE-R is 
administered to a mock patient.  Each vignette will be shown in its entirety only once; you 
are to score each ACE-R sheet as you watch the vignettes, just as you would in clinical 
practice.  There should be no conferring throughout the study.  There will be time to total 
up each of the ACE-R forms between vignettes.  Scoring guides are available on request 
should you wish to refer to them when scoring the forms up between vignettes. 
 
In your pack there is a sheet detailing which version of the ACE-R (A,B or C) should be 
used for each vignette.  That sheet also contains what the correct answers for the 
orientation section of the ACE-R are for each vignette, please refer to it when scoring this 
section. 
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Appendix 2.6: Orientation information 
 
 
Vignette 1 
 
Version B of the ACE-R 
 
Orientation information: 
 
 Monday 16th June, 2009 
 Govan Health Centre 
 1st Floor 
 
 
 
 
 
Vignette 2 
 
Version A of the ACE-R 
 
Orientation information: 
 
 Monday 16th June, 2009 
 Parkview Resource Centre 
 Ground Floor 
 
 
 
 
 
Vignette 3 
 
Version C of the ACE-R 
 
Orientation information: 
 
 Monday 16th June, 2009 
 Elderpark Clinic 
 1st Floor 
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Appendix 2.7: Research ethics committee letter 
West of Scotland Research Ethics Service 
West of Scotland REC 3 
Ground Floor, The Tennent Institute 
Western Infirmary 
38 Church Street 
Glasgow G11 6NT 
Telephone: 0141 211 2123  
Facsimile: 0141 211 1847 
08 October 2009 
Miss Stephanie Crawford 
Trainee Clinical Psychologist 
NHS Greater Glasgow and Clyde 
Section of Psychological Medicine 
Gartnavel Royal Hospital 
1055 Great Western Road 
Glasgow G12 0XH 
Dear Miss Crawford 
Study Title: A Novel Approach to Investigating the Reliability of the 
Addenbrooke's Cognitive Examination - Revised (ACE-
R) 
REC reference number: 09/S0701/92 
Protocol number: Version 7 
The Research Ethics Committee reviewed the above application at the meeting held on 
01 October 2009. Thank you for attending to discuss the study. 
Ethical opinion 
The members of the Committee present gave a favourable ethical opinion of the above 
research on the basis described in the application form, protocol and supporting 
documentation, subject to the conditions specified below. 
Ethical review of research sites 
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start 
of the study (see “Conditions of the favourable opinion” below). 
Conditions of the favourable opinion 
The favourable opinion is subject to the following conditions being met prior to the start of 
the study. 
Management permission or approval must be obtained from each host organisation prior 
to the start of the study at the site concerned. 
For NHS research sites only, management permission for research (“R&D approval”) 
should be obtained from the relevant care organisation(s) in accordance with NHS 
research governance arrangements.  Guidance on applying for NHS permission for 
research is available in the Integrated Research Application System or at 
http://www.rdforum.nhs.uk. Where the only involvement of the NHS organisation is as a 
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Participant Identification Centre, management permission for research is not required but 
the R&D office should be notified of the study. Guidance should be sought from the R&D 
office where necessary. 
Sponsors are not required to notify the Committee of approvals from host organisations. 
It is responsibility of the sponsor to ensure that all the conditions are complied 
with before the start of the study or its initiation at a particular site (as applicable). 
Approved documents 
The documents reviewed and approved at the meeting were: 
Document    Version    Date    
Covering Letter    11 September 2009  
REC application    11 September 2009  
Protocol  Version 7  27 July 2007  
Investigator CV    11 September 2009  
Participant Information Sheet  Version 2  10 September 2009  
Participant Information Sheet: Additional  Version 2  10 September 2009  
Participant Consent Form  Version 1  10 September 2009  
Letter of invitation to participant  Version 1  10 September 2009  
Questionnaire: Vignette 1  Version 2  10 September 2009  
Questionnaire: Vignette 2  Version 2  10 September 2009  
Questionnaire: Vignette 3  Version 2  10 September 2009  
Examinations Officer Letter    30 June 2009  
Project Proposal Assessment Mark Sheet    29 June 2009  
Letter -  Research Director    28 July 2009  
Scoring and Instructions Guide       
  
Membership of the Committee 
The members of the Ethics Committee who were present at the meeting are listed on the 
attached sheet. 
Statement of compliance  
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK. 
After ethical review 
Now that you have completed the application process please visit the National Research 
Ethics Service website > After Review 
You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure. If you wish to make your views 
known please use the feedback form available on the website. 
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
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•€Notifying substantial amendments 
•€Adding new sites and investigators 
•€Progress and safety reports 
•€Notifying the end of the study 
The NRES website also provides guidance on these topics, which is updated in the light 
of changes in reporting requirements or procedures. 
We would also like to inform you that we consult regularly with stakeholders to improve 
our service. If you would like to join our Reference Group please email 
referencegroup@nres.npsa.nhs.uk. 
09/S0701/92 Please quote this number on all correspondence 
With the Committee’s best wishes for the success of this project 
Yours sincerely 
Liz Jamieson 
Committee Co-ordinator on behalf of Dr Robert McNeill – Acting Chair 
Email: Liz.Jamieson@ggc.scot.nhs.uk 
Enclosures: List of names and professions of members who were present at the 
meeting and those who submitted written comments 
“After ethical review – guidance for researchers”  
Copy to: Darren Gibson, Research and Development  
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Appendix 2.8: Major research project proposal 
 
 
 
Major Research Project Proposal 
A Novel Approach to Investigating the Reliability of the Addenbrooke's Cognitive 
Examination – Revised (ACE-R) 
 
Matriculation Number: 0206932 
Date of Submission: 27th July, 2009 
Version No. 7 
Word Count: 3903 
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Title of Project 
 
A Novel Approach to Investigating the Reliability of the Addenbrooke's Cognitive 
Examination – Revised (ACE-R) 
 
Abstract 
Background 
Dementia rates are expected to markedly increase in the future.  There is a consensus that 
early diagnosis is an important element in the management of the Dementia population.  
Cognitive screening tools which aid dementia diagnosis are commonly used in clinical 
practice.  Dementia screening tools need to be both valid and reliable.  The 
Addenbrooke's Cognitive Examination – Revised (ACE-R) is showing promise as a 
dementia screening tool.  The ACE-R is becoming increasingly used in clinical practice; 
however there is as yet, no study which solely and explicitly investigates its reliability.  
This study plans to investigate the reliability of the ACE-R using a novel approach 
involving multiple raters and filmed vignettes. 
 
Aims 
This study aims to explore how accurately the ACE-R is scored by multiple raters; both in 
terms of its total and sub-category scores.  It will also consider whether scoring accuracy 
is effected by participant experience in using the ACE-R.   
 
Methods 
Scoring consistency will be investigated using three filmed vignettes.  These vignettes 
will be of the ACE-R being administered to older adult actors (mock patients).  These 
vignettes will have a pre-determined ‘true score’.  Study participants will be required to 
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complete ACE-R scoring sheets for each vignettes.  The participants will be Trainee 
Clinical Psychologists and Community Psychiatric Nurses (CPNs) working in Older 
Adult Community Mental Health Teams (CMHT).   
 
Applications 
 
This study will develop an original approach to investigating reliability in a clinically 
relevant way.  It will also address a gap in the literature on the ACE-R by providing 
information on its reliability. 
 
Introduction 
 
Dementia is a disorder involving progressive, global, cognitive decline (Lezak et al., 
2004); Alzheimer's disease is the most common type of dementia.  In 2005 a group of 
international experts estimated that worldwide there were 24.3 million people with 
dementia (Ferri et al., 2005).  Ferri et al. (2005) further estimated that this prevalence rate 
would double every 20 years; meaning that by 2020 an estimated 42 million people 
worldwide will have dementia.  Wimo et al. (2007) estimated that in 2005 the societal 
cost of dementia was 315.4 billion U.S. Dollars worldwide.  These studies make it clear 
that Dementia is a disorder which requires increasing attention on a global scale. 
 
From a Scottish perspective, in April 2008 the Scottish Government announced that 
Dementia had been made a National Health Priority and that each NHS board was to 
deliver improvements in early diagnosis and management of dementia by 2011 (Scottish 
Government Health and Community Care, 2008).   
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There is a general consensus that early diagnosis of dementia is desirable.  The 
Comptroller and Auditor General's report (2007) stated that early detection enables for 
earlier intervention and gives: “people the opportunity to make choices and plan for the 
future while they are still relatively well” (p.43).  Shulman and Feinstein (2003) also 
identified several potential benefits of early detection, including: providing the 
opportunity for patients to participate in clinical research at a relatively early stage; 
highlighting a need to monitor risks for driving and allowing cognitive enhancer drug 
treatments to be commenced early. 
 
The Role of Cognitive Screening in Dementia Diagnosis 
According to the National Institute for Health and Clinical Excellence (NICE), Clinical 
Guideline 42, Dementia: Supporting people with dementia and their carers in health and 
social care (2006) a Dementia diagnosis should be made following a comprehensive 
assessment involving: history taking, cognitive, mental and physical examination and 
medication review.  Cognitive assessment tools are well established aids in this diagnostic 
process.  Woodford and George (2007) state that cognitive assessment in the elderly is 
typically used for three reasons: i) screening for cognitive impairment; ii) differential 
diagnosis and iii) rating disease severity or monitoring disease progression.  In clinical 
practice, where time constraints are omnipresent, the possibility of achieving an objective, 
quantitative measure of cognitive functioning following a short administration period is 
desirable.  This may explain why, in the arena of cognitive assessment, recent decades 
have witnessed the development of various dementia screening tools to aid the diagnostic 
process.   
 
It has been suggested that the fundamental aim of screening tools is to infer from the 
patient's score, compared to reference norms, the likelihood of a genuine cognitive 
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impairment (Cullen et al., 2007).  Cullen et al. (2007) emphasise that the success of 
screening tools developed to meet this aim will be dependent on their statistical 
robustness.  Clinical practice requires such statistical robustness to be achieved in the 
minimum time possible using an instrument that is easy to administer (Cullen et al., 
2007).  Furthermore Cullen et al. (2007) noted that the ideal screen should also provide 
rich qualitative data; thus enabling a symptom orientated approach to assessment and 
preventing over emphasis on cut off scores.  Cut off scores distinguish between patients in 
terms of the presence or absence of the condition under study (Lezak et al., 2004).  It is 
unlikely there will ever be a cognitive screening tool which will always accurately make 
this distinction (Lezak et al., 2004).  Therefore professionals using cognitive screening 
tools should know their cut off scores; understand their limitations and extrapolate 
relevant qualitative information from the tool. 
 
Currently, the use of one established, standardized screening test remains elusive (Gifford 
and Cummings, 1999; Mathuranath et al., 2000).  Opinions also differ regarding how 
dementia screening tests should be applied and whose responsibility they should be.  
Cullen et al. (2007) suggested three main screening purposes: i) brief assessment in the 
doctor's office; ii) large scale screening programmes in the community and iii) domain 
specific screening to guide further assessment (tertiary care clinicians).  Cullen et al.'s 
(2007) review of screening tools concluded that those most likely to be useful: 
“..have good sensitivity and specificity for all dementia types in unselected populations, 
and which elicit information about key cognitive abilities, which can then be compared 
with neuropsychological profiles in different types of dementia” (p.9). 
The Addenbrooke's Cognitive Examination – Revised (ACE-R) was identified as one of 
the tools which best matched this criteria. 
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Measurement Issues in Cognitive Screening Tools 
It is generally agreed that the value obtained from any measurement is a combination of 
the 'true score' and a degree of measurement error (McDowell, 2006).  The fundamental 
difficulty across all cognitive measures is that the true score is never precisely known; it 
can only be inferred from the value obtained (Trochim, 2006).  It is essential cognitive 
tools minimise the degree of measurement error they create: thus making the value they 
obtain as accurate a reflection of the underlying true score as possible.  Measurement 
errors can be categorised into random errors and systematic errors.  Random errors 
increase group variability but do not affect the average performance (overall mean) of the 
group.  Systematic errors tend to be consistently either positive or negative and thus are 
considered a source of bias (Trochim, 2006).   
 
There are numerous sources of potential measurement error, which can affect the 
reliability of a cognitive tool, these may be broadly conceptualised into three categories: 
i) client factors e.g. client motivation, attention, and mood; ii) contextual factors e.g 
setting in time and place; iii) rater factors e.g. administration and scoring issues.   
 
Reliability refers to a measurements consistency.   Inter-rater reliability assesses whether 
the tool is administered and scored consistently between raters (Trochim, 2006).  If a tool 
is not consistently administered and scored by different raters then its clinical utility is 
limited.  Traditionally inter-rater reliability has been investigated by assessing agreement 
between a few (expert) raters across numerous trials.  Such designs assume that high 
agreement indicates strong inter-rater consistency for both administration and scoring.  
However by assessing agreement between a few raters these designs fail to investigate 
administration and scoring reliability across multiple raters in a clinical setting.  
Furthermore by considering administration and scoring collectively these designs may fail 
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to detect important aspects of each.  Inter rater reliability studies may benefit from using 
greater numbers of raters and investigating administration and scoring separately. 
 
Once initial research has identified a cognitive screening tool as promising the primary 
question usually becomes whether or not its usefulness can be maintained when it is 
applied to a more varied, clinical population.  Another important, yet less frequently 
studied, aspect which affects the generalisability of a tool is the consistency with which it 
is administered and scored by a range of professionals other than the few experts who 
initially developed it.  An originally designed rater reliability study could address such an 
issue. 
 
The ACE-R as a Dementia Cognitive Screening Tool 
Cullen et al. (2007) identified the ACE-R as a cognitive screening tool currently used in 
domain specific screening (tertiary care settings, e.g. Older Adult CMHTs) which may be 
potentially useful in primary care settings.  However until it is validated in non-specialist 
settings this suggestion remains purely speculative (Cullen et al., 2007). 
 
The Addenbrooke's Cognitive Examination (ACE) was originally designed to detect mild 
dementia and differentiate Alzheimer’s disease from Fronto-temporal Dementia 
(Mathuranath et al. 2000).  In 2006 Mioshi et al. published an article introducing the 
revised version: the ACE-R.  The ACE-R was designed as a dementia screening test, 
sensitive to early indicators of cognitive deterioration.   
 
The ACE-R has five sub-categories, each representing a cognitive domain, these are: 
Attention and orientation (18 points), Language (26 points), Fluency (14 points), Memory 
(26 points) and Visuo-spatial (16 points).  The five sub-category scores are summed 
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together to produce an overall total score (maximum 100 points).  Mioshi et al. (2006) 
identified two ACE-R cut off scores (88 –  sensitivity: 0.94, specificity: 0.89 and 82 – 
sensitivity: 0.84, specificity: 1.00).   
 
In 2006 the ACE-R was recommended by the Scottish Intercollegiate Guidelines 
Network, (SIGN 86),  as a means of improving initial cognitive testing for dementia.  It 
therefore seems likely that its use will become increasingly pervasive.   
 
ACE-R Reliability 
In their original validation study of the ACE Mathuranath et al. (2000) did not assess its 
inter-rater reliability but acknowledged that this would be a useful focus for future 
research.  Mathuranath et al. (2000) theorised that rater related bias should be low since 
the ACE assesses cognitive function in an objective manner.  Mioshi et al. (2006, p.1078) 
stated that the ACE-R had underwent “design changes to make the test easier to 
administer”.  This suggests that the rater reliability of the ACE-R should be high.   
 
Molloy and Standish (1997) highlighted that, without provision of clear instructions, 
multiple raters inevitably administer and score a test in their own way and different 
groups may develop their own unique standardization procedures.  This raises reliability 
issues both between professionals and between different health groups.  The ACE-R 
Administration and Scoring guide aims to prevent such issues by providing descriptions 
of acceptable responses for each item.  However in a busy clinical setting this guide may 
not be regularly referred to.  In addition the guide does not provide advice on how to use 
the ACE-R as a tool for gathering qualitative information or for differentiating between 
different types of dementia. 
 
111 
 
As far as this proposal is aware there is no published study looking explicitly at the ACE-
R’s rater reliability.  Current circumstances suggest that the ACE-R is increasing in 
popularity and thus is being used by increasing numbers of professionals.  It therefore 
seems timely to investigate the ACE-R’s rater reliability.  Conclusions from such a study 
could also provide information relevant to future cognitive screening research.   
 
The Current Study 
Cognitive screening tools which aid dementia diagnosis are commonly used in clinical 
practice.  The ACE-R has been identified as one such tool.  The reliability of the ACE-R 
has not been explicitly studied and given the likelihood that it will be increasingly used in 
clinical settings this seems a potentially useful research area.   
 
This study plans to focus on the rater reliability of the ACE-R using a novel approach 
wherein several raters participate and scoring consistency is investigated whilst 
administration is kept constant.  Several items in the ACE-R require a degree of rater 
interpretation.  Based on the clinical experiences of Older Adult Clinical Psychologist's it 
is hypothesised that professionals are more likely in clinical practice to give clients “the 
benefit of the doubt”, which may in turn lead to the 'test score' being inflated from the 
'true score'.  This may become troublesome if over scoring means the score obtained is 
above the cut off whilst the underlying ‘true score’ is below the cut off.  In other words, if 
over scoring causes conclusions to be drawn which do not accurately reflect the 
underlying true score.  Such over scoring by several professionals may lead to systematic 
measurement errors.  It seems probable that over scoring will be more likely on the visuo-
spatial and language sub-categories because they require more subjective judgements 
when scoring. 
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Furthermore, it may be hypothesised that if individuals do not frequently refer to the 
ACE-R Administration and Scoring guide they may develop their own unique scoring 
methods.  This in turn is likely to impact on the inter rater reliability of the measure.  
Between rater scoring discrepancies may also be affected by rater experience of using the 
ACE-R.  Logically one would expect that scoring accuracy would be better for raters who 
regularly use the ACE-R.   
  
Aims  
 
The primary aim is to investigate how accurately the ACE-R is scored by multiple raters; 
particularly in terms of whether participants consistently over score the ACE-R.  In 
addition there will be exploration of whether scoring consistency varies across ACE-R 
sub-categories and whether scoring accuracy is effected by experience of using the ACE-
R.  Any sub-categories identified as having partcipant scores which significantly differ 
from their true scores will be further investigated to identify which items within them are 
causing the greatest discrepancies.  Finally there will be general considerations regarding 
participant ability to correctly identify ACE-R cut off scores and participant reports of 
their next steps in clinical practice following ACE-R testing. 
 
Primary Hypothesis 
The participant ACE-R total scores will differ significantly from the ACE-R true scores. 
 
Secondary Hypothesis 
a) Participant scores on the ACE-R sub-categories which involve more subjective 
judgements (visuo-spatial and language) will significantly differ from the 'true' subtest 
scores.  
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b) Scoring accuracy may be related to participant experience using the ACE-R 
 
Plan of Investigations 
 
Participants 
There will be two groups of participants: 
i) Older Adult CMHT community psychiatric nurses (CPNs) who use the ACE-R 
routinely in their clinical practice.   
ii) Trainee Clinical Psychologists currently completing the University of Glasgow's 
Doctorate in Clinical Psychology course who have used the ACE-R whilst on placement 
in the NHS. 
Participants will be included if they have administered and scored the ACE-R 
independently in clinical practice on at least one older adult client.  Participants will be 
excluded if they have not used the ACE-R in clinical practice; that is they have not 
completed it with an older adult patient.  If participants have only observed the ACE-R 
being used or practiced its use with another colleague this will not be considered 
sufficient use and they will be excluded from the study.   Some of the CPN participants 
will have received a one off Clinical psychology led training session on how to use the 
ACE-R during 2008.  Although participants will not be excluded if they did not 
participate in such training all participants will be required to state whether they did or did 
not participate in this training.  Participants will be invited by letter to take part in the 
study.   The researcher will visit each of the Older Adult CMHT team meetings and the 
three Trainee Clinical Psychology year groups to provide a brief overview of the study. 
 
Measures 
The Addenbrooke's Cognitive Examination – Revised (ACE-R) is the primary outcome 
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measure.   
 
Design and Research Procedure 
This study has developed a novel, clinically relevant method for investigating inter-rater 
reliability.  The study plans to use filmed vignettes of the researcher administering the 
ACE-R to older adult actors (mock patients).  These vignettes will have pre-determined 
‘true scores’ and will allow scoring consistency to be investigated separately from 
administration consistency.  Scripts for the research vignettes will be developed by an 
advisory group of Older Adult Clinical Psychologists.  These scripts will reflect 
performance on the ACE-R suggestive of different Dementia profiles.  The agreed 
vignettes will have 'true' overall and sub-category scores.  There will be three vignettes in 
total.   The University of Glasgow media services will film and produce the vignettes.  
The actors will be professional actors recruited through the NHS Role play coordinator.  
The actors will be given  information on the purpose of the study and how their 
performances will be used.  Each actor will perform one vignette, having learned it 
beforehand and will be paid for their time. 
 
Study participants will be required to complete ACE-R scoring sheets in conjunction with 
watching the vignettes.  Participants will view each vignette in its entirety once and will 
not be permitted to pause or rewind any part of it.  The researcher will ensure that 
participants are able to hear and see the vignettes clearly.  The vignettes will be viewed 
either on a laptop or projector screen.  The vignettes will be shown to participants in 
groups (with a minimum of three participants in each group).  After watching each 
vignette participants will be permitted time to complete their scoring of that particular 
ACE-R form.  The ACE-R Administration and Scoring Guide will be available to view at 
this time.  In addition to scoring the vignettes the participants will be asked to complete 
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an additional form detailing: their profession and details of their ACE-R experience.   
 
Settings and Equipment 
A lap top, and at times projector will be required to show the vignettes.  The NHS Greater 
Glasgow Older Adult Psychology service is able to provide such equipment.  The study 
will be conducted in clinic rooms or lecture/study rooms; the researcher will be able to 
book time in such settings through the Older Adult Psychology Department and the 
University of Glasgow.  ACE-R scoring sheets, ACE-R Administration and Scoring 
guides and additional information sheets will also be required.   
 
 Justification of Sample Size 
 The power calculation was based on the one sample t-test because it will be the main 
method for statistical analysis.  Since there have been no previously published studies on 
the ACE-R's inter-rater reliability there is no data available to base the power calculation 
on.   It was felt that a small effect size would translate into only a few points variation 
from the true score which would not threaten the overall conclusions drawn from the 
ACE-R.  Whereas a medium effect size would translate into a difference significantly 
large enough that it could alter interpretation of the ACE-R results, which could in turn 
influence a wider assessment process.  Therefore the power calculation  determined the 
number of participants necessary for a medium effect size used the conservative values 
of: a p-value of 0.05 and a power of 0.8.  When these values for a one sample t-test were 
entered into G*Power 3.010 (Faul, Erdfelder et al., 2008, from www.psycho.uni-
duesseldorf.de/abteilungen/aap/gpower3/ ) the results indicated that a minimum of 34 
participants would be required.   
 
It is hypothesised that both participant groups will over score the ACE-R and therefore no 
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significant difference is expected between the participant groups.  However at analyses 
the groups will be initially compared to ensure there are no significant differences 
between them.  If there are significant differences, the groups will be analysed separately 
and comparisons of their sub-category scores conducted to detect where the differences 
lie.  To ensure power is not affected if the groups are significantly different a minimum of 
34 participants will be recruited from each of the participant groups. 
 
Data Analysis 
The details of data analysis outlined below will be carried separately out for each 
vignette.  Descriptive statistics will be used to gain an overall understanding of the data.  
In particular proportions and standard deviations will be used to analyse the variation of 
test scores from the 'true score'.  Percentages will also be used to determine how many 
participant correctly identified the relevant cut off scores; total and sub-category true 
scores.   The primary hypothesis will be analysed using a one sample t-test to compare 
whether the ACE-R scores obtained significantly differ from the predetermined ACE-R 
'true scores'.  Secondary hypothesis a) will also be assessed using one sample t-tests to 
investigate whether the results obtained differ significantly from the true subtest scores.  
Secondary hypothesis b) will be analysed using correlational methods.   
 
Health and Safety issues 
 
Researcher and Participant Safety Issues 
No significant health and safety issues are expected.  Participants will all be NHS staff 
and the study will be conducted in either NHS or University of Glasgow premises.   
 
Ethical Issues  
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The study will not progress until ethical approval is obtained from the West of Scotland 
Research Ethics Committee 3 and Greater Glasgow and Clyde Research and 
Development approval is also obtained.  The participants in the study will be NHS staff.  
Participants will be required to give informed consent prior to their participation.  
Following participant completion of the vignettes they will be debriefed.  This debrief 
will include information on how the data will be used and details of the follow up process 
detailed below.  The debrief will also highlight that performance on the vignettes is not a 
reflection of overall professional competency and that individual results will not be 
revealed.  All data gathered will be anonymous.  It is not anticipated that the study will 
cause  participants distress.  However, if the results indicate that as a group the 
participants have made significant scoring errors this may threaten their feeling of 
professional competency.  To overcome this, the researcher will provide written feedback 
to all participants on the overall findings of the study and also offer every participant the 
opportunity to participate in one training session.  Depending on participant uptake on the 
offer for a training session the researcher will host as many training sessions as required 
to ensure all participant who would like to take part in a training session have the 
opportunity do so.  Training session content will focus on addressing any areas that the 
study identified as being significantly mis-scored by the participant group.  The actors 
involved will not be CMHT patients and will not have cognitive difficulties.  The actors 
will be fully briefed prior to their participation.  The vignettes used shall be developed by 
a small panel of Clinical Psychologists working within Older Adult services and therefore 
will not be based on individual clients.   
 
Financial issues  
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The University of Glasgow Media Services will be available free of charge with the 
exception of the recoup of digital tape stock and DVDs, which will come to £35.  Pene 
Herman-Smith, NHS role coordinator, will provide professional older adult actors to 
perform the vignettes.  Each actor requires a fee of £125 for their time.  Other financial 
costs will be minimal.  
 
Practical Applications 
This study will develop an original approach to investigating inter-rater reliability in a 
clinically relevant way.  It will also address a gap in the literature on the ACE-R by 
providing information on its inter-rater reliability. 
 
Timetable 
Obtain Course Approval     by August 2009 
Complete scripts for vignettes    by September 2009 
Obtain ethical approval     by October 2009 
Film vignettes       by November 2009 
Data collection      Nov 2009 – Jan 2010 
Data analysis and write up     Completed by Jun 2010 
Written summary of results sent to all participants  Completed by Aug 2010 
Follow up training sessions     Offered throughout Aug   
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